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ABSTRACT
Host defense against infection and disease relies on the reciprocal communication between the
immune and neuroendocrine systems where sex hormones exert negative and positive feedback
actions on immune functions. Indeed, sex hormones have been implicated in gender dimorphic
immune response and in the potentiation of immune-related disorders. The female hormone
estrogen plays a role as an immunomodulator and may exert immunosuppressive and
immunostimulatory effects. Though many studies focus on estrogen’s role in immunity within
the female reproductive tract and autoimmunity, the modulatory effects of estrogen on vaccine
responses are largely unexplored. The insufficient efficacy of some vaccines in certain target
populations, as for example the elderly population, is well recognized. Hormones fluctuate
throughout an individual’s life, and females in particular undergo several necessary reproductive
(pregnancy and menopause) and lifestyle (oral contraceptive use) changes which involve sex
hormones. Vaccine efficacy might be influenced by endogenous estrogen levels or by exogenous
estrogen administration. Therefore, in the pursuit of improved vaccine efficacy, it is necessary to

consider such hormonal factors and their contribution to immune status. We have studied
estrogen’s role in modulation of vaccine responses using a mouse ovariectomy model where
exogenous estrogen delivery can be controlled. Our studies included two different types of
vaccines, a bacterial toxoid formulation and a bacterial secreted protein formulation. Results
from these studies indicate that estrogen enhances vaccine-specific antibody production by likely
supporting a general TH2 pathway and also modulates expression of genes encoding molecules
critical in innate immune signaling and required for development of proper adaptive immune
responses and antigen clearance through antibody-mediated mechanisms. The level at which
estrogen modulates antibody responses appears to be dependent on the route of vaccine
administration. The enhancement of specific humoral responses may involve mechanisms
involving TLR2 and antibody Fc receptor expression on macrophages, cells that link innate and
adaptive immune responses. Advances in our understanding of the relationship between sex
hormones and the immune system may provide new insights into the mechanisms by which
hormones act and thus may be exploited to guide the design of future vaccine strategies.
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CHAPTER 1
Introduction and Study Objectives

The primary function of the immune system is to protect the host from invasion of foreign
organisms by distinguishing “self” from “non-self”. While there is a high degree of
interconnectivity between its components, the immune system is generally divided into two
subsystems, the innate and the adaptive immune systems (Kuby 2007). Innate immunity
provides the first line of defense against infection. Its disease-resistant mechanisms are nonspecific and though the response is immediate in action, it is short-lived. In contrast, adaptive
immunity is much more specific and takes longer to activate. It results in immunological
memory which can augment itself to respond more quickly and with greater specificity to future
encounters with the same pathogens. To some extent, the distinction between innate and adaptive
immunity is vague, because it is now evident that innate immune signaling is required for
activation of adaptive immunity (Delves and Roitt 2000). Both systems are highly interactive and
cooperative, producing a combined response more effective than either branch could produce on
its own, and one that provides protection against a diverse and rapidly-evolving array of
pathogens.
The innate immune system consists of molecules and cells that distinguish host components from
those of infectious agents, in part by recognizing conserved constituents of microorganisms.
Innate immune activation occurs within hours of contact and its efficacy is not influenced by
previous exposure. Phagocytes play a pivotal role in the innate immune response. Upon
activation by microbial detection, they release cytokines and chemokines which go on to signal a
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wide array of functions and responses, including inflammation. The major phagocytic cells
include neutrophils and macrophages, which are specialized to internalize and destroy
microorganisms, and dendritic cells (DC). DC act as dedicated antigen-presenting cells (APC)
that display antigen for recognition by naïve lymphocytes of the adaptive immune system and
activate their differentiation into effector cells. Proper activation requires specialized costimulatory signals along with antigen recognition; in this way DC provide a crucial link between
the recognition of microbial components and activation of adaptive immune responses. Other
cells of the innate immune system, such as basophils, mast cells and natural killer (NK) cells, are
not phagocytic, and use other mechanisms to kill bacteria. For example, NK cells, which play a
role in the host-rejection of both tumors and virally infected cells, kill cells by signaling them to
undergo apoptotic cell death.
The interaction between phagocytes and pathogens or foreign substances is facilitated in several
ways. Pathogens may be coated with molecules known as opsonins which facilitate
phagocytosis. Opsonins include complement proteins of the innate immune system and
antibodies, or immunoglobulins, of the adaptive immune system. Another way that phagocytes
interact with pathogenic molecules is through direct binding of pattern-recognition molecules to
conserved structures on the pathogen. A number of these molecules have been identified, but
perhaps the most important of these are the molecules known as toll-like receptors (TLR). TLR
are membrane-spanning proteins expressed on a variety of different cell types, including DC and
monocytes/macrophages as well as B cells and epithelial and endothelial cells (van Duin and
Shaw 2007). They recognize and bind conserved structures on microbial pathogens. The
microbial structures, termed pathogen-associated-molecular-patterns (PAMPs), are repetitive
structures that include extracellular bacterial structures and nucleic acids. TLR are considered
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pattern recognition receptors that, by their recognition and interaction with PAMPs, result in cell
activation and thus cytokine secretion and phagocytosis.
Currently, 11 human TLRs and 13 murine TLRs have been described (Table 1.1). Common
microbial and synthetic ligands for TLRs 1-9 have been identified in both humans and mice (van
Duin and Shaw 2007). Ligands for TLR1 and 2, and 2 and 6, are Gram-positive bacteria and
yeast cell wall components, while the predominant Gram-negative bacterial product, LPS, is a
ligand for TLR4. Other products such as dsRNA (poly I:C), bacterial flagellin, immiquimod, and
CpG oligodeoxynucleotides (ODN) have been identified as ligands for TLR 3, 5, 7, and 9,
respectively. The interaction between a TLR and its ligand results in the secretion of antibacterial peptides, defensins, and pro-inflammatory cytokines such as TNF-α and IL-6, which
initiate an inflammatory response to clear the invading organism. Furthermore, the inflammatory
response results in the recruitment of cells of the adaptive immune system, including B and T
cells, to initiate clearance of the pathogens by generating a specific immune response. Therefore,
TLR-dependent activation of antigen presenting cells represents a crucial step not only for the
innate response, but also for ensuing mobilization of the adaptive immune system. Indeed,
inherent defects in TLR signaling have been described in humans and are associated with greater
susceptibility to bacterial infections (Ku, Yang et al. 2005).
The adaptive immune system is triggered when a pathogen evades the innate immune barriers of
protection. As opposed to the innate response, the adaptive immune response is not present prior
to encounter with a specific pathogen. Taking several days to develop, it antigen receptor
molecule from a pre-existing repertoire recognizing a diverse array of distinct antigen
specificities that arises from a recombinant gene rearrangement process (Delves and Roitt 2000).
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Table 1.1. Toll-like receptors, their ligands, the pathogens from which they are derived and the
phenotype displayed by TLR knockout studies (Carpenter and O'Neill 2007).

TLR

Ligand

Target Pathogen

TLR1

Triacylated lipoproteins

Mycobacteria

TLR2

Peptidoglycan, lipoproteins,
zymosan

Gram-positive bacteria
S. aureus, S. pneumoniae, yeast
and other fungi

TLR3

Double stranded RNA
(dsRNA)

Viruses

LPS

Gram-negative bacteria,

TLR4

Phenotypes of knockout mice

Cytokine production
Cytokine production

Cytokine production,
Resistance
Pro-inflammatory cytokines
(TNF-α, IL-6, IL-1),
Proliferation of splenic B cells,
hypo-responsive

TLR5

Flagellin

S. typhimurium, P. aeruginosa

TLR6

Diacylated lipoproteins,
zymosan

Mycobacteria, yeast and fungi

TLR7/8

Single-stranded RNA
(ssRNA)

Viruses, HIV, Denge virus
influenza

TLR9

CpG DNA

Bacterial DNA

No obvious phenotype because
of TLR4 redundancy
Cytokine production
Cytokine release from
dendritic cells, CD40 not upregulated
Dendritic cell maturation,
Splenocyte proliferation,
Inflammatory cytokines

TLR10

Unknown

Unknown

Unknown

TLR11

T. gondii Uropathogenic bacteria

TLR12

Profilin, uropathogenic
bacteria
Unknown

Unknown

Unknown

TLR13

Unknown

Unknown

Unknown

Survival
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The adaptive immune response has several unique and critical functions. First of all, it has the
ability to recognize specific “non-self” antigens in the presence of “self”, within the context of
antigen presentation. Second, it is designed to generate responses that are tailored to maximally
eliminate specific pathogens or pathogen-infected cells, a process achieved by clonal selection.
Finally, an additional hallmark of the adaptive immune system is its ability to develop
immunological “memory”, which results in the mounting of a stronger and much more rapid
response to the same pathogen upon subsequent infection.
Adaptive immunity is mediated by lymphocytes, which fall into two major classes: T
lymphocytes and B lymphocytes (Kuby 2007). Lymphocytes constitute 20-40% of the body’s
white blood cells and 99% of the cells in the lymph. B lymphocytes, or B cells, originate and
mature in the bone marrow and are responsible for the production of antibodies, the major
effector molecules of humoral immunity. T lymphocytes, or T cells, originate in the bone
marrow and mature in the thymus and are the effector cells of cell-mediated immunity. These
circulate in the blood and lymph and carry out their respective functions in the tissues and
lymphoid organs.
T cells are further divided into 2 subsets, which are each responsible for distinct roles within the
immune system: T helper (TH) lymphocytes and cytotoxic T (CTL) lymphocytes, distinguished
from each other by the restricted surface expression of either CD4 or CD8 molecules,
respectively. TH cells orchestrate the activity of a number of other cells and processes of the
immune system depending on the type of cytokine profile that they secrete. There are two main
functional categories: T helper 1 (TH1) cells and T helper 2 (TH2) cells. TH1 cells secrete
cytokines that stimulate an immune response against intracellular pathogens or tumors, resulting
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in an activation pathway that favors a strong cell-mediated response. The cytokines secreted by
TH1 cells include IL-2, IL-12 IFN-γ and TNF-α (Salem 2004). TH2 cells secrete cytokines that
stimulate an immune response against extracellular pathogens, resulting in an activation pathway
that favors a strong humoral response. Cytokines secreted by TH2 cells include IL-4, IL-5, IL-10
and IL-13 (Salem 2004). The type of TH cell response generated (cellular vs. humoral) is dictated
by the cytokine milieu produced in response to the signal received upon infection. A third subset
of T helper cells, termed TH17 cells, also exists and is thought to play a role in inflammation,
autoimmunity and allergy (Mangan, Harrington et al. 2006; Schmidt-Weber, Akdis et al. 2007).
These cells are characterized by expression of IL-17, IL-6, TNF-a and IL-22 (Harrington, Hatton
et al. 2005; Park, Li et al. 2005; Chung, Yang et al. 2006; Mangan, Harrington et al. 2006;
Zheng, Danilenko et al. 2007). Because of their role in tissue inflammation by supporting
neutrophil infiltration and survival, matrix degradation and induction of pro-inflammatory
cytokines in structural cells leading to pathology, there is currently a complex topic of
controversy regarding whether TH17 cells are beneficial or harmful to the host (Schmidt-Weber,
Akdis et al. 2007).
The other type of effector T cell is the CTL. Pathogenic microorganisms whose proteins gain
access to the cell cytoplasm are considered “endogenous” antigens, which stimulate CTLs.
Activation of CTLs involves the recognition of antigenic peptides in association with MHC class
I molecules on APCs (Kuby 2007). MHC class I molecules are expressed by all somatic cells,
excluding red blood cells. Two major mechanisms for target cell killing by CTLs have been
described. One mechanism involves the secretion of perforin and its insertion in the plasma
membrane of target cells leading to osmotic lysis. Alternatively, CTLs may express Fas ligand
on their surface which binds to Fas on the target cell membrane to induce apoptosis. In addition
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to killing infected cells directly, CTLs can elaborate a number of cytokines including TNF-alpha
and lymphotoxin (Shames 2002).
Humoral immunity is another major component of the adaptive immune system. B cells and
immunoglobulins are the main mediators of the humoral response during infection.
Immunoglobulins, or antibodies, are proteins present on the B-cell membrane, and can be
secreted once the B cell becomes activated or matures into a plasma cell. Specific interaction of
membrane-bound antibody with antigen necessarily results in proliferation of antigen-specific Bcell clones with the capability of secreting antibodies which interact with antigen in the blood
and tissues. While in circulation, antibodies seek out and neutralize pathogens, thus eliminating
them. All immunoglobulins share certain structural features, participate in specific binding to
antigen and carry out an array of effector functions that contribute to pathogen clearance. They
are composed of 82-96% protein and 4-18% carbohydrate (Spiegelberg 1974). The
immunoglobulin protein “backbone” consists of two identical heavy and two identical light
chains, linked together by disulfide bonds. Each chain is further divided into domains that make
up the variable and constant regions of the molecule. At the amino terminal of the molecule, one
variable domain from a light chain and one variable domain from a heavy chain make up the
antigen-binding portion. The highly diverse amino acid sequences at these regions confer unique
antigen binding properties to the antibody. The rest of the antibody molecule has much less
variation than the variable domains and therefore the immunoglobulin domains that comprise
these parts of the molecule are called constant domains. Light chains have one constant domain
whereas heavy chains have either 3 or four, depending on the type of heavy chain. The COOHterminal of the constant domains of the heavy chains (CH) contain what is known as the Fc
portions. It is through the Fc portion that other immune system components bind
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immunoglobulins to initiate immune effector functions. For this reason, receptors that bind this
portion of the immunoglobulin are called Fc receptors (FcR) (Ravetch and Kinet 1991).
While the variable regions of antibody are responsible for binding to antigen, the CH regions are
responsible for a variety of interactions with other proteins, cells and tissues that result in the
effector functions of the humoral response. The major effector functions of antibodies include
opsonization, which promotes antigen phagocytosis by macrophages and neutrophils;
complement activation, which activates a pathway that leads to the generation of a collection of
proteins that can perforate cell membranes; and antibody-dependent cell-mediated cytotoxicity
(ADCC), which leads to killing of antibody-bound target cells. These effector functions rely on
the interaction between CH regions and other immune cells/molecules. The various antibody
classes differ in their CH regions and therefore not all classes of immunoglobulins have the same
functional properties.
The binding of IgG to FcR on leukocytes is important for many of the effector functions of IgG.
There are four classes of FcγR identified in mammals: FcγRI (CD64), FcγRII (CD32), FcγRIII
(CD16) (Siberil, Dutertre et al. 2007). Recently, a new member of the mouse FcγR family was
identified, known as FcγRIV, however no human counterpart has yet been identified
(Nimmerjahn, Bruhns et al. 2005; Nimmerjahn and Ravetch 2006). Binding of IgG to activating
FcγR (FcγRI and FcγRIII) induce antibody-dependent cell cytotoxicity (ADCC), endocytosis of
immune complexes followed by antigen presentation, phagocytosis and release of proinflammatory cytokines. By contract, IgG binding to inhibitory FcγR (FcγRII) regulate immune
responses by inhibiting the activation of B lymphocytes, monocytes, mast cells and basophils,
induced through activating receptors(Nimmerjahn and Ravetch 2006). The activating and
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inhibitory receptors transmit their signals via immunoreceptor tyrosine-based activation (ITAM)
or inhibitory motifs (ITIM), respectively (Ravetch and Lanier 2000). Besides differences in
function, the different classes of FcγR vary in cellular distribution and display different affinities
for IgG along with characteristic isotype specificities (Figure 1.1). IgG/FcγR immune complex
formation and the resulting effects are therefore well-regulated processes that provide a means
by which antibodies, products of the adaptive immune system, can recruit key cellular elements
of innate immunity such as macrophages and NK cells.
Five classes of immunoglobulins present in both humans and mice (IgG, IgA, IgM, IgD, and
IgE) have been distinguished on the basis of non-cross-reacting antigenic determinants in regions
of highly conserved amino acid sequences in the constant regions of their heavy chains
(Ballieux, Bernier et al. 1964; Terry and Fahey 1964; Schur 1972).
IgG is the most abundant class found in serum, constituting about 80% of the total serum
immunoglobulin. The IgG molecule is a monomer consisting of 2 gamma heavy chains and 2
kappa or two lambda light chains. This molecule is further broken down into 4 subclasses in
humans, designated as IgG1, IgG2, IgG3 and IgG4, based on their relative concentration in
normal serum and their frequency of occurrence as myeloma proteins (Kunkel, Fahey et al.
1966). Though mice produce IgG1, IgG2 and IgG3,the presence of IgG4 is strain-dependent
(Martin and Lew 1998). Immunoglobulin subclasses are encoded by different germline constant
heavy (CH) chain genes whose DNA sequences are 90-95% homologous. The structural
characteristics that distinguish these subclasses from each other are the amino acid sequence and
size of the hinge region as well as the number and position of the inter-chain disulfide bonds
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Figure 1.1. Human leukocyte Fc receptors.
Relative affinities of various ligands for receptors are indicated in decreasing order, starting with
the isotype with the highest affinity. The Ig domains are color-coded according to their subunit
homology. Whereas some receptors signal directly through activation (green rectangles) or
inhibition motifs (orange rectangles) in their ligand-binding α-chain, others depend on
membrane association with the Fc γ-chain to allow signaling through the γ-chain ITAM. Basos,
basophils; Eos, eosinophils; Langs, Langerhans cells; Macs, macrophages; Monos, monocytes;
Neuts, neutrophils; GPI, glycosylphosphatidylinositol; ND, not determined; S-IgA, secretory IgA
(Woof and Burton 2004; Shi, McIntosh et al. 2006).
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between the two heavy chains. Though subtle, these differences affect the biological activity of
the molecule (Table 1.2).
IgM accounts for 5-10% of total serum immunoglobulin. Monomeric IgM is expressed as
membrane-bound antibody on B cells. IgM is secreted by B cells in a pentameric form consisting
of five monomeric units held together by disulfide bonds. IgM is the first immunoglobulin class
produced in a primary response to antigen and is the first immunoglobulin to be synthesized by
the neonate. Because of its high valency, IgM is more efficient than IgG in viral neutralization
and complement activation.
IgA constitutes 10-15% of total immunoglobulin in serum, however it is the predominant class
present in external secretions such as breast milk, saliva, tears and mucus of the bronchial,
genitourinary and digestive tracts. In serum, IgA exists primarily as a monomer although
polymeric forms are sometimes seen. The IgA of external secretions is known as secretory IgA
because it contains a secretory component that is responsible for transporting polymeric IgA
across cell membranes. IgA-secreting plasma cells are present in the mucous membrane surfaces,
which are the primary entry way for most pathogenic organisms. Therefore, because of its
localization at these sites, IgA can bind such pathogens and prevent attachment to mucosal cells,
thereby inhibiting colonization.
IgE exists in extremely low average serum concentration (0.3%), however it plays an important
role in mediating the immediate hypersensitivity reactions that are responsible for the symptoms
of hay fever, asthma, hives and anaphylactic shock. IgE binds to Fc receptors on the surface of
blood basophils and tissue mast cells. Cross-linkage of receptor-bound IgE molecules to antigen
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Table 1.2. Immunoglobulin classes/subclasses differ in structure and function (Kuby 2007).

Immunoglobulin Class/Subclass
IgM

IgG1

IgG2

IgG3

IgG4

IgA

IgE

IgD

Pentamer

Monomer

Monomer

Monomer

Dimer

Dimer

Monomer

Monomer

Serum
Concentration
(mg/ml)

1.5

9

3

1

0.5

3.5

0.0003

0.03

Complement
Activation

++

+

+/-

++

-

-

-

-

Placental
Transfer

-

+

+/-

+

+

-

-

-

Phagocyte
Fc Receptor
Binding

?

++

+/-

++

+

-

-

-

Neutralization

+

++

++

++

++

++

-

Opsonization

+

+++

-

++

+

+

-

Presence in
External
Secretions

Mucus
etc.

Milk

Milk

Milk

Milk

Mucus
etc.

-

Structure

-

-

++ = high; + = moderate; +/- = minimal; - = none; ? = questionable
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induces degranulation of these cells, resulting in the release of granules and molecules,
manifesting in an allergic response.
IgD is the most recently identified immunoglobulin present in serum, constituting about 0.2% of
total immunoglobulin in serum. IgD, along with IgM, is the major membrane bound
immunoglobulin expressed by naïve B cells. Although its function has not been completely
understood, it is thought to play an important role in affinity maturation (Roes and Rajewsky
1993) and B cell activation (Kim and Reth 1995).
Immunoglobulins are made as both secreted antibodies and membrane-bound receptors for
antigen displayed on the surface of B cells. The membrane-bound immunoglobulin is one part of
a complex that forms the B cell antigen receptor (BCR). The BCR also contains a disulfidelinked heterodimer of two other polypeptides, Igα and Igβ, which are made only in B-lineage
cells. Each of these polypeptides contains a signaling function in their cytoplasmic domains. All
five antibody isotypes can be expressed as membrane-bound that also form BCR in this way.

Lymphocyte activation and effector mechanisms

The activation of B and T lymphocytes is mediated by antigen-presenting DC in the B and T cell
zones of the secondary lymphoid organs (spleen and lymph nodes) (DeFranco 2007). DC capture
antigen at the site of infection or antigen entering the lymphoid tissue by blood or lymph, and
then mature and display antigen as peptide fragments bound to surface molecules for recognition
by T cells. In the case of B cells, intact antigen is displayed in complexes with complement
components or antibodies that bind to receptors on follicular DC surface. These cells play a
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central part in stimulating the production of antibodies with increased affinity for antigen
(affinity maturation) and reflects a process in which the immunoglobulin genes undergo mutation
and B cells with higher affinity immunoglobulin resulting from these mutations are selectively
induced to proliferate (clonal selection). IgM and IgD are co-expressed on the surface of mature
B cells, possess single antigenic specificity, and act as the initial BCR that binds antigen. After
antigenic stimulation, B cells can differentiate into IgM-secreting plasma cells, which is the case
in a primary immune response. Other activated B cells undergo a further process of
recombination known as isotype switching. This occurs at the immunoglobulin heavy chain gene
locus and results in the expression of different classes of antibodies (IgG, IgA or IgE) with the
same antigenic specificity, yet able to perform unique effector functions (Kuby 2007).
Differentiation into effector cells requires interaction of naïve lymphocytes with antigen. This
recognition occurs via receptors generated through a unique mechanism of genetic
recombination that confers virtually unlimited diversity in antigen binding specificity. The major
receptors involved are BCR and T cell receptors (TCR). Structurally, each of these receptors
contains a highly variable antigen-binding region (V region) and an invariant region known as
the constant region (C region), both of which are separately encoded in the germ-line DNA.
During lymphocyte ontogeny, the DNA encoding these receptors undergoes programmed
rearrangement to generate different segments which recombine to generate a receptor repertoire
of vast diversity. After gene rearrangement and receptor expression, but before maturation,
antigen binding initiates one of two processes: clonal deletion of cells which bear receptors for
self antigens and clonal expansion of lymphocytes with receptors specific for the inducing
antigen. This distinction is the basis for antigen-specific adaptive immune responses.
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While B cells are capable of recognizing antigen alone, T cells recognize and interact only with
antigen that has been processed and presented in association with MHC molecules. MHC
molecules (also called human leukocyte antigens [HLA] in humans) are subdivided into class I
molecules, which are found on all nucleated cells and class II molecules, which are found on
specialized antigen-presenting cells (APCs) such as dendritic cells, macrophages, B cells, and
selected activated endothelial or epithelial cells. TH (CD4+) cells only recognize antigen
presented by class II MHC molecules and CTLs (CD8+) only recognize antigen presented by
class I MHC molecules. T-cell activation requires 2 signals. The first signal occurs through
antigen/MHC binding to the TCR and is known as “signal 1”. An additional signal, “signal 2”, is
provided by interaction between the co-stimulatory molecule CD28 on the T cell and CD80 or
CD86 (also designated B7.1 and B7.2 respectively) on the APC. Activation of B cells requires
signaling through the BCR and co-receptors such as CD19, CD21, or CD22. The combined
antigen receptor- and co-receptor-derived signals define the degree of B cell activation and the
strength of humoral immune responses. Activation of naïve T and B cells through this
recognition and the subsequent up-regulation of appropriate co-stimulatory molecules is a
requirement for differentiation into effector cells and successful pathogen elimination through
the adaptive immune response.
T cell activation by recognition of the antigen on the target cell surface triggers the release of
soluble mediators that act on the target cell. In the case of CD8+ CTL, these are cytotoxic
mediators that kill cells infected with intracellular pathogens (e.g. viruses). Activation of naïve B
cells occurs when antigen binds to surface immunoglobulin. The antigen is then internalized and
presented on the surface where it is recognized by antigen-specific T helper cells which activate
the B cell to proliferate and differentiate into antibody-secreting plasma cells. Cytokines secreted
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by T helper cells influence not only the antigen binding regions of the antibodies, resulting in
affinity maturation, but also direct the effector functions of the antibodies produced by plasma
cells, resulting in production of antibodies of classes determined by their constant regions
(isotypes). Following activation of naïve B and T cells, specific humoral and cell-mediated
immune responses ensue.
B cells need two signals to initiate activation. Most antigens are T-dependent, requiring T cell
help for maximal antibody production. With a T-dependent antigen, the first signal comes from
antigen cross linking BCR and the second from its interaction with a T cell. When the antigen is
first recognized and bound by the BCR, it becomes internalized, processed and presented as a
peptide on MHC class II molecules. Recognition of this processed antigen by TH (CD4+)
lymphocytes and the subsequent activation of these cells constitute the critical events in the
humoral (antibody-mediated) response. The antigen-MHC II complex forms the epitope that is
recognized by antigen-specific T cell receptors on the surface of the CD4+ cells. T helper cells
become activated and provide co-stimulatory signals and secrete cytokines (predominantly IL-4,
IL-5 and IL-6) that lead to B cell proliferation and differentiation into effector memory cells and
antibody-secreting plasma cells.
The ability of the immune system to respond rapidly upon re-exposure to a given antigen relies
on long-lived plasma cells and the differentiation of memory cells. Memory responses differ
from the primary response to antigen is several ways. First, because the population of antigenspecific cells has already undergone expansion and most of the changes required for effector
function, they are much quicker. Second, in the case of B cells, the antibodies have undergone
affinity maturation and are more effective than those produced in a primary response (Pulendran
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and Ahmed 2006). For these reasons, a subsequent infection with a given antigen usually does
not lead to disease. The development of vaccines that safely and efficiently induce immune
memory is one of the most important goals of immunological research.

Immune Response to Vaccination

Immunity to a particular pathogen relies on the host’s ability to mount a specific response against
that pathogen. Immunity can be achieved through passive or active immunization. Passive
immunization can occur by the transfer of preformed antibodies to a recipient through natural or
artificial means. The goal of active immunization is to elicit protective immunity and
immunologic memory so that subsequent exposure will induce a heightened immune response as
well elimination of the pathogen (DeFranco 2007). An example of active immunization is
vaccination. Vaccines are designed to direct the immune system towards preventing infection
and/or disease by mimicking the immune pathway elicited by a natural infection. Achieving this
requires the activation of adequate innate as well as adaptive immune signals.
Mimicking the natural primary response to infection, initiation of a vaccine response relies on
neutrophils, macrophages and DC of the innate immune system. These cells coordinate
downstream activation of the adaptive response by secreting a variety of inflammatory mediators
and cytokines. Upon activation, these cells become potent activators of T cells by virtue of upregulation of MHC and co-stimulatory molecules on their surface. Activated, or mature, DC are
the only APC capable of activating naïve T cells. After antigen processing and presentation
through the exogenous pathway by APC, expressing MHC II molecules, CD4+ T cells can
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specifically recognize the antigen. CD4+ cells then become activated and differentiate into either
TH1 or TH2 subsets.
Immunization also activates the humoral response. The primary humoral response is
characterized by the production of antibody-secreting plasma cells and memory B cells. The
kinetics of this response varies depending on the nature of the antigen, the route of
administration, the dose and the presence of immune enhancers. In general, this response is
characterized by a lag phase, during which naïve B cells undergo clonal selection and
differentiation into plasma and memory cells (Figure 1.2). Following this is the logarithmic
phase, in which serum antibody levels increase until they reach a peak, which then they plateau
and then eventually decline. Generally occurring within the first two weeks of immunization,
IgM is secreted initially, followed by IgG. The subsequent development of a secondary response
relies on the existence of a population of memory B cells and memory T cells. Antigenic
activation of these cells generates a secondary antibody response which is characterized by a
shorter lag period, more rapid recognition, greater magnitude and longer lasting response as
compared with the primary response. In addition, the antibodies secreted in the secondary
response have a higher affinity for the antigen and as a result of isotype switching, classes other
than IgM predominate. The population of memory B cells in a secondary response is larger and
more easily activated as compared with naïve B cells. Upon activation, this memory response
continues to increase, reaching maximal levels around six months and persisting for years.
Immunization activates a primary response. If an immunized individual is later exposed to the
pathogen, the immune system behaves as a secondary response to infection, where plasma cells
are already primed to produce high levels specific antibodies. Both activated T cells and
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Figure 1.2. Primary and secondary immune responses.
Following initial exposure to an antigen the antibody response develops gradually over a period
of days, reaches a low plateau within 2-3 weeks, and usually begins to decline in a relatively
short period of time. When the antigen is encountered a second time, a secondary (memory)
response causes a rapid rise in the concentration and increased affinity of antibody. The high
levels of antibody in the serum may persist for a relatively long period of time.

19

antibody-secreting plasma memory cells are necessary to achieve an overall response is
heightened and more rapid, thus efficiently protecting the body from infection and illness.
Immunization programs have led to the elimination and/or control of several different infectious
diseases, including smallpox, polio, measles, mumps, rubella, Haemophilus influenzae type B
disease, pertussis, tetanus and diphtheria (Rosenthal and Zimmerman 2006). The most successful
vaccines are ones mediated through the induction of protective antibodies (Plotkin 2001).
Current targets for vaccine development include more challenging infectious agents which
require induction of CD4+ and CD8+ cellular responses (Plotkin 2005). These include viral
agents such as human immunodeficiency virus (HIV), cytomegalovirus and severe acute
respiratory syndrome coronavirus; bacteria such as Pseudomonas aeruginosa, Neisseria
gonorrhea and Mycobacterium tuberculosis; and parasitic diseases such as malaria (O'Hagan,
MacKichan et al. 2001; Rosenthal and Zimmerman 2006).
There are currently four types of vaccine formulations that are licensed for humans, including
live attenuated, killed, purified subunit and recombinant subunit vaccines (Table 1.3). A live
attenuated vaccine relies on decoupling virulence from induction of protective immunity. These
are usually effective because they contain the three main elements needed for potent immune
induction, the target antigen for induction of specific responses, PAMPs for induction of innate
immunity and efficient delivery resulting from the natural invasiveness of the original organism
(Ulmer, Valley et al. 2006). The organism is rendered attenuated by being subjected to serial
passage in broth or cell culture, followed by selection for reduction of virulence and maintenance
of immunogenicity in animal models. One important limitation of live attenuated organism-based
vaccines is the risk of the organism reverting to virulence. In a killed vaccine, all of the antigens
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Table 1.3. Examples of types of vaccines (Kuby 2007).

Type of vaccine

Disease target

Live attenuated

Mumps, Measles, Polio (Sabin vaccine), Rubella,
Rotavirus, Tuberculosis, Varicella, Yellow fever

Inactivated or killed

Cholera, Influenza, Hepatitis A, Polio (Salk
vaccine), Rabies

Subunit

Hepatitis B, Pertussis, Streptococcal pneumonia

Conjugate

Haemophilus influenzae type B, Streptococcal
pneumonia, Neisseria Meningitidis

Recombinant

Hepatitis A, B

DNA

Tuberculosis, Hepatitis B, HIV (experimental)
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of the organisms are available to the immune system, but the organism itself is rendered
harmless, usually by treating it with formaldehyde. Because of their inability to replicate in vivo,
these are generally less immunogenic than live vaccines, and therefore are often administered
with adjuvants to increase their potency. Because of lack of exogenously-administered antigen
accessibility to endogenous MHC-I antigen presentation pathways, killed vaccines do not
effectively elicit cell-mediated immunity. Therefore, killed vaccines are mostly used for eliciting
antibody-mediated protection.
Recombinant vaccines are those in which genes for desired antigens are inserted into a vector,
usually a virus. The vector expressing the antigen may be used as the vaccine, or the antigen may
be purified and injected as a subunit vaccine. Antigens which do not elicit protective immunity
or those which are too toxic can be eliminated from the vaccine, and proteins expressed in a
virus, even if it is not the original pathogen, are more likely to preserve their native
conformation.
Since the natural immune response has evolved to provide optimal protection against infectious
disease, the ideal vaccine should elicit the steps and processes of natural immunity. While the
current vaccine approaches are relatively safe and have several protective advantages, a general
problem is that the vaccines alone are often poorly immunogenic. Unlike attenuated live
vaccines, killed whole organism or subunit vaccines generally require the addition of an adjuvant
to be effective (Petrovsky and Aguilar 2004). Adjuvants were originally described as substances
used in combination with a specific antigen that produced a more robust immune response than
the antigen alone (Ramon 1924). Adjuvants can be used to boost the immunogenicity of vaccines
in several different ways. They can (1) increase the immunogenicity of weak antigens; (2)
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enhance the speed and duration of the immune response; (3) modulate antibody avidity,
specificity, isotype or subclass distribution; (4) stimulate cell mediated immunity, (5) promote
the induction of mucosal immunity; (6) enhance immune responses in immunologically
immature, or senescent individuals; (7) decrease the dose of antigen in the vaccine and reduce
costs; or (8) help to overcome antigen competition in combination vaccines (O'Hagan,
MacKichan et al. 2001).
The goal of a vaccine is to trigger the host immune system and mount adaptive immune
responses of sufficient magnitude and duration, including B-cell-mediated antibody protection
and/or specific T-cell-mediated cellular responses to a protective antigen in order to prevent
infection or reduce severity of disease. It is now well-known that to achieve this, a vaccine
should contain an adjuvant that efficiently activates the innate immune system to elicit such
antigen-specific immune responses. A variety of immuno-stimulatory compounds appear to be
TLR ligands and are currently being used experimentally or in clinical trials within vaccine
formulations as an adjuvant (Ishii and Akira 2007). However, recent evidence has shown that
some conventional adjuvants (Alum, Incomplete Freund’s Adjuvant [IFA] and Complete
Freund’s Adjuvant [CFA]) as well as unconventional adjuvant-containing vehicle activate the
innate immune system in a TLR-independent manner (Gavin, Hoebe et al. 2006; Janssen, Tabeta
et al. 2006). Such alternative pathways that have been demonstrated to mediate adjuvant-induced
innate and adaptive immune responses in a TLR-independent manner include intracellular innate
receptors such as NOD-like receptors (NLR) and RIG-like receptors (RLR) (Creagh and O'Neill
2006; Meylan, Tschopp et al. 2006; Ishii and Akira 2007).
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Adjuvants ultimately enhance antigen delivery by directly or indirectly facilitating uptake by
APC, especially DC. Since these cells have the unique capacity to present antigen to naïve T
cells in the lymph nodes, the principal mode of action of many particulate adjuvants (e.g.
micoparticles, emulsions, liposomes, Iscoms etc.) are to promote uptake of the antigen by DC at
the site of injection. Successful delivery of antigen to the lymph nodes and will not ensure the
induction of an immune response because the presence of antigen alone constitutes only ‘signal
1’. Induction of a successful immune response requires the co-presence of ‘signal 2’. Signal 2 is
represented by co-stimulatory molecules and cytokines, which are provided by APC and
contribute to the priming of T helper cells.
A key issue in adjuvant development is toxicity. Safety concerns have restricted the development
of adjuvants since alum was first introduced more than 50 years ago (Edelman 1997). Many
experimental adjuvants have advanced to clinical trials but most have proven unsuitable for
human use due to local and systemic toxicity (Table 1.4), Despite extensive evaluation of a large
number of candidates over many years, the only adjuvants currently approved by the U.S. Food
and Drug Administration are aluminum based mineral salts (generally referred to as alum)
(Allison and Byars 1991; Brewer 2006; Rosenthal and Zimmerman 2006). Alum up-regulates
co-stimulatory signals on human monocytes and promotes the release of IL-4 (Ulanova,
Tarkowski et al. 2001) and is thought to act by forming an antigen depot at the site of inoculation
(O'Hagan, MacKichan et al. 2001). Alum adsorption may also contribute to a reduction in
toxicity for some vaccines, due to the adsorption of contaminating endotoxin (Shi, HogenEsch et
al. 2001). Despite these attributes, alum is considered a relatively poor adjuvant in many
situations, particularly for antibody induction to protein subunits (Gupta 1998) and for inducing
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Table 1.4. Selected examples of vaccine adjuvants (O'Hagan, MacKichan et al. 2001)
Adjuvant System

Example

Mineral Salts

Aluminum hydroxide*, Aluminum phosphate,
Calcium phosphate*

Immuno-stimulatory adjuvants

Cytokines (e.g. IL-2, IL-12, GM-CSF)

Microorganism-derived adjuvants MDP derivatives, Bacterial DNA (CpG oligo’s),
LPS, MPL and synthetic derivatives
Lipid particles

Emulsions (e.g. Freund’s, SAF, MF59*)

Particulate adjuvants

Iscom’s, Liposomes, polymeric microspheres,
nano-beads, virus-like particles

Mucosal adjuvants

Heat labile enterotoxin (LT), Choler toxin (CT),
Mutant toxins (e.g. LTK63 and LTR72)

Nucleic acid-based adjuvants
* Currently included in approved vaccines
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Many factors may influence the immune response to vaccination. These include the presence of
maternal antibody, nature and dose of antigen, route of administration, and the presence of
adjuvants. In addition, host factors such as age, nutritional status, genetics, coexisting disease
factors and immune status, may also affect the response.

Gender and Hormonal Influences on Immune Function

As mentioned earlier, proper immune function and maintenance of homeostasis relies on the
immune system’s ability to discriminate between self and non-self as well as the ability to
regulate inflammation and therefore tissue damage and pathogenesis. Any malfunction in this
regulation may lead to immune dysfunction and, ultimately, disease. One manifestation of
immune dysfunction is immunodeficiency. This results when the immune system’s ability to
fight off disease is either compromised or entirely absent, rendering the host particularly
vulnerable to opportunistic infections. Thus, the individual is considered to be “immunocompromised”. In a healthy immune state, self-reactive lymphocytes are deleted via the process
of negative selection or made unresponsive to self ligands/antigens through tolerance during
development of the immune system. Autoimmunity, another form of immune dysfunction,
results from the inability to discriminate “self” from “non-self”, which leads to a pathologic
inflammatory response and ultimate development of autoimmune disease (Shames 2002).
Gender is one of the most important epidemiological risk factors for the development of
autoimmune diseases (Da Silva 1999), where the risk is 2.7 times higher in females as compared
to males (Jacobson, Gange et al. 1997). Table 1.5 lists data on the prevalence of autoimmune
diseases in females as compared to males.
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Consistent with differences in prevalence of autoimmune diseases, evidence indicates that even
basic immune responses differ between males and females. In response to immunization, females
mount more vigorous T cell responses, have higher levels of serum immunoglobulins (Eidinger
and Garrett 1972; Weinstein, Ran et al. 1984) and shorter skin allograft rejection time (Grossman
1984; Olsen and Kovacs 1996). Females have higher CD4+ T cell numbers than men (Amadori,
Zamarchi et al. 1995) and also mount consistently higher Th2 responses than men (GironGonzalez, Moral et al. 2000).
There is now a large body of evidence suggesting that sex hormones in males and females are
significant factors responsible for this gender dimorphism. Since sex hormones differ between
males and females as well as within different reproductive stages in females, a lot of research has
focused on the detailed effects of sex hormones on immune function. Sex hormones modulate a
variety of immune mechanisms including thymocyte maturation and selection, cell trafficking,
cytokine and chemokine production, lymphocyte proliferation, and expression of adhesion
molecules and HLA class I molecules (Wilder 1995; Olsen and Kovacs 1996). Estrogens have
stimulating effects on B cell functions which may be dependent on inhibition of suppressor T
cells. Cumulative data follows the general trend that estrogen enhances B cell activity and B-cell
mediated diseases but suppresses T cell activity and T-dependent conditions. Testosterone, on
the other hand, appears to suppress both B cell and T cell-mediated responses and virtually
always suppresses expression of the disease (Da Silva 1999). Physiological levels of estrogens
tend to enhance B cell mediated responses and antibody production both in vivo and in vitro, as
well as cellular responses such as transplant rejection and tumor-associated immunity, whereas
progesterone and testosterone tend to depress these processes (Sthoeger, Chiorazzi et al. 1988).
Additionally, both the incidence and severity of many autoimmune diseases have been found to
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Table 1.5. Gender differences in autoimmune disease prevalence

Disorder

Female: Male ratio

Hashimoto's disease/ hypo-thyroiditis

50:1

Systemic lupus erythematosus
Sjogren's syndrome
Antiphospholipid syndrome

9:1
9:1
9:1

Primary biliary cirrhosis

9:1

Mixed connective tissue disease
Chronic active hepatitis
Graves' disease/hyperthyroiditis

8:1
8:1
7:1

Rheumatoid arthritis

4:1

Scleroderma
Myasthenia gravis
Multiple sclerosis

3:1
2:1
2:1

Chronic idiopathic thrombo-cytopenic purpura

2:1

Type 1 diabetes mellitus

2:1

American Autoimmune Related Diseases Association
(www.aarda.org)
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be influenced by a range of female-related endocrinological changes involving sex steroids, such
as puberty, pregnancy, menopause, use of oral contraceptives and aging (Da Silva 1999). In
conditions such as multiple sclerosis (MS) and rheumatoid arthritis (RA), severity of the disease
decreases during pregnancy, particularly during the third trimester, when progesterone and
estradiol levels peak. Interestingly, disease severity flares up again during the post-partum, when
hormone levels drop (Nelson and Ostensen 1997; Confavreux, Hutchinson et al. 1998). On the
other hand, patients with systemic lupus erythematosus (SLE) may worsen or remain unchanged
throughout pregnancy (Petri 1994). This is explained by the fact that in pregnancy there is a shift
towards TH2 pathways leading to increased activation of the humoral response and a decreased
cellular response. In SLE, humoral responses are a significant pathogenic factor thus disease
exacerbation, whereas RA and MS are disorders related to cellular TH1 pathways (Lahita 1986;
Holmdahl 1989).
In human and animal experimental models, the female sex hormones estrogen and progesterone
have been shown to regulate both innate and adaptive immunity. Much of the existing data is
based on studies which examine immunity within the female reproductive tract (FRT), mainly
because this serves as the first site of immunological contact with pathogens such as Chlamydia,
HIV and human papillomavirus (HPV) and site of diseases such as gonorrhea and syphilis. The
vagina, cervix and uterus contain the necessary immune cells responsible for both innate and
specific immunity, although the numbers and functions of these cells vary significantly
throughout the phases of the reproductive cycle. This phenomenon is believed to be correlated
with and controlled by changes in the levels of estrogen and progesterone, hence the role of these
hormones in susceptibility to infection, gender differences in immune function and development
in autoimmune disease.
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Primarily due to the female dominance in the incidence of autoimmune disease, estrogen, in
particular has attracted significant interest as an immunomodulator. Murine models of
autoimmunity have supported this role. Estrogen acts on multiple immune processes including
lymphocyte and monocyte development, dendritic cell function, T cell responses, cytokine
regulation, B cell expansion and survival, antibody responses, and NK cell activity (Reviewed in
(Lang 2004). There is a wealth of clinical and laboratory data generated over the past 20 years
demonstrating that sex hormones, particularly estrogen, affect the immune system. However, the
mechanisms by which estrogen modulates such processes as well as how its effects are regulated
is complex and requires the understanding of the interactions between the immune system with
the neuro-endocrine system.

Interaction between the Immune and Neuroendocrine Systems

Hormonal influences on immune function occur through the necessary interaction of the immune
system with the neuroendocrine system through common receptors to neurotransmitters,
hormones and cytokines. The hypothalamus-pituitary-adrenal (HPA) serves as a key element of
this communication pathway. Activation of the HPA axis is known to serve the body’s response
to stress, which can be defined as any physical or psychological stimulus that disrupts the body’s
homeostasis.
There are three main glands that comprise the anatomy of the HPA axis. The hypothalamus,
located in the lower central part of the brain, functions to regulate metabolism and body
temperature. It secretes hormones that regulate the release of hormones in the pituitary gland.
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Referred to as releasing hormones, these include corticotrophin releasing hormone (CRH) and
gonadotropin-releasing hormone (GnRH) which are secreted and carried directly to the pituitary
gland to signal secretion of stimulating hormones. The pituitary gland, located at the base of the
brain beneath the hypothalamus, is considered to be the "master gland" of the body because it
secretes a range of hormones that control the functions of virtually all physiologic processes in
the body. The main hormone secreted by the pituitary is adreno-corticotropin hormone (ACTH),
which stimulates the adrenal glands to produce glucocorticoids. Every nucleated cell in the body
expresses glucocorticoid receptors; hence the widespread effects of glucocorticoids on most
systems of the body, including metabolic, endocrine, nervous, cardiovascular and immune
systems. The pituitary also secreted the stimulating hormones, follicle stimulating hormone
(FSH) and luteinizing hormone (LH) which stimulate the gonads to produce and release the male
and female sex hormones.
Inflammation resulting from immune aggression during the innate or adaptive immune response
involves the release of pro-inflammatory cytokines. These cytokines can activate the HPA axis,
resulting in the release of glucocorticoids. In turn, the glucocorticoids exert negative feedback
onto immune cells to suppress further synthesis and release of cytokines, thereby protecting the
host from detrimental consequence of an overactive immune response (e.g. tissue damage,
autoimmunity, septic shock) (Figure 1.3). Cytokine receptors have been detected at all levels of
the HPA axis, and therefore, each level can serve as an integration point for immune and
neuroendocrine signals. In addition, cytokines are synthesized in the brain, the anterior pituitary
and the adrenal gland. The major cytokines that are known to be involved in HPA activation are
IL-1, IL-2, IL-6, TNF-alpha and interferon (IFN) (Bumiller, Gotz et al. 1999).
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Figure 1.3. Interactions between the immune system and the HPA axis in an inflammatory
reaction.
Activation of the immune system through bacterial aggression induced the production of proinflammatory

cytokines

that

stimulate

the

HPA
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producing
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immunosuppressive GC, which negatively regulate further pro-inflammatory cytokine
production. Gonadal stimulation by pituitary hormones, LH and FSH, results in sex steroid
hormone secretion, which can also directly stimulate immune cells by acting on specific
hormone receptors in these cell types. GC, glucocorticoids. CRH, corticotropin release hormone;
ACTH, adrenocorticotrpin release hormone; LH, luteinizing hormone; FSH, follicular
stimulating hormone.
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Glucocorticoids regulate a wide range of immunological processes, such as cell proliferation,
inflammation, and inhibition of trafficking of T, B, and NK cells, eosinophils, basophils,
macrophages, and monocytes and induction of apoptosis in mature T and B cells and peripheral
blood lymphocytes. In addition, glucocorticoids may alter downstream adaptive immune
responses by causing a shift from cellular

(TH1/inflammatory) to humoral (TH2/anti-

inflammatory) type immune responses (Chrousos 2000). These events could partially explain the
immuno-suppression that is associated with stress. Therefore, glucocorticoids can modulate
immune/inflammatory processes by stimulating as well as suppressing immune function,
depending on the type of immune response, the immune compartment, and the cell type involved
(Silverman, Pearce et al. 2005). HPA-activated release of glucocorticoids represents a potent
negative feedback mechanism which allows the body to have tight control of the local immune
response, inhibiting this defense mechanism from endangering the body’s integrity (Gaillard and
Spinedi 1998). In addition to suppressing HPA axis activating-immune processes,
glucocorticoids act on specific receptors within the hypothalamus and pituitary to regulate its
own production (Buckingham, Loxley et al. 1996; Da Silva 1999).
In the HPA response to immune stimuli, a gender dimorphism exists (Da Silva 1999). Female
rats have higher basal levels of plasma corticosterone compared to males and lower levels of
pituitary glucocorticoids receptors, with their expressions being estrogen dependent (Turner
1990). In experimental animals, females also have higher and more prolonged ACTH or stressinduced plasma corticosterone levels than males. Estrogens generally increase HPA responses,
whereas androgens suppress it (Da Silva 1999). Gonadectomy in both male and female mice
leads to enhanced HPA axis and immune responses to endotoxin, which can be reversed by
androgen treatment in both sexes (Spinedi, Suescun et al. 1992). Sex steroid receptors are present
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in the adrenals (Gaillard and Spinedi 1998). These observations clearly indicate that sex steroids
modulate both immune and HPA axis activities.

Estrogen Mechanism of Action
The major estrogens include estradiol, estrone and estriol. Their effects are mediated through
interaction with specific intracellular receptors. These receptors are members of the nuclear
receptor super-family of transcription factors. The estrogen receptor (ER) is present in two
subtypes, ER-α and ER-β, encoded by two distinct genes (Kuiper, Enmark et al. 1996;
Mosselman, Polman et al. 1996; Couse and Korach 1999). They share a high degree of amino
acid conservation in their DNA binding domains (97%) and exhibit a significant, but lesser
degree of homology in their ligand binding domains (58%). Both receptors are localized in
reproductive tissues, as well as non-reproductive tissues including cells of the immune system,
cardiovascular system, central nervous system and bone (Lubahn, Tan et al. 1989; Krege,
Hodgin et al. 1998; Couse and Korach 1999; Dupont, Krust et al. 2000; Mendelsohn 2000).
Within the immune system, ERs are present in B lymphocytes (Suenaga, Evans et al. 1998;
Benten, Stephan et al. 2002), T lymphocytes (Cohen, Danel et al. 1983; Suenaga, Evans et al.
1998; Benten, Stephan et al. 2002), monocytes (Weusten, Blankenstein et al. 1986; Suenaga,
Mitamura et al. 1996; Suenaga, Evans et al. 1998; Stefano, Prevot et al. 1999), neutrophils
(Molero, Garcia-Duran et al. 2002) and NK cells (Curran, Berghaus et al. 2001; Henderson,
Saunders et al. 2003).
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ER-α is the dominant subtype expressed throughout the FRT and its ablation results in infertility
due to defects in sexual behavioral expression, neuro-endocrine gonadotropin regulation,
ovulation, uterine function, and post-pubertal mammary gland morphogenesis. The ER-α subtype
also plays an essential role in male fertility and mediates many non-reproductive activities of
estrogen including regulation of bone-resorption, post-natal bone growth, cardiovascular
endothelial regeneration, adipogenesis and sexual behavior (Couse and Korach 1999). In
contrast, ER-β ablation results in less severe phenotypic consequences with regard to estrogen
signaling. ER-β is expressed in both the male and female reproductive tracts in a pattern which
differs from that of ER-α and its ablation results in a sub-fertile phenotype restricted to impaired
female ovarian function (Krege, Hodgin et al. 1998). Expression of ER-β has also been detected
in non-reproductive tissues including bone-forming osteoblasts, epiphyseal chondrocytes and
cardiovascular and central nervous systems (Mendelsohn 2000; Wang, Andersson et al. 2001).
Estrogenic effects are mediated by genomic or non-genomic mechanisms (Figure 1.4). In a
genomic mechanism of action, estrogenic ligands activate ER as a transcription factor by
inducing a conformational change(s) that leads to nuclear translocation, dimerization, and
binding to specific steroid receptor response elements (SRE) in promoters of primary target
genes. Activated ER recruits co-activators that are essential for assembly of a productive
transcription complex at the promoter. In a non-genomic action of ER, ER associates with
cytoplasmic- and/or cell membrane–signaling molecules in an estrogen-dependent manner. This
extra-nuclear interaction promotes the Shc-Src-Raf–MAPK kinase (MEK)–MAP kinase
phosphorylation cascade. Because MAPK can directly or indirectly activate other transcription
factors, this pathway can potentially regulate distinct or complementary sets of genes from those
regulated by nuclear ER pathways. As mentioned, ER acts on cells of the immune system as well
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Figure 1.4. Estrogen receptor mechanism of action.
In a genomic mechanism of action, ligands (triangles) activate ER as a transcription factor by
inducing a conformational change(s) that leads to nuclear translocation, dimerization, and
binding to specific steroid receptor response elements (SRE) the target gene promoter. In a nongenomic action of ER, ER associates with cytoplasmic- and/or cell membrane–signaling
molecules in an estrogen-dependent manner. This promotes the Shc-Src-Raf–MAPK kinase
(MEK)–MAP kinase phosphorylation cascade. MAPK can directly (solid arrows) or indirectly
(dashed arrows) activate other transcription factors (TF). Adapted from (Edwards and
Boonyaratanakornkit 2003).

36

as breast, bone, brain and uterus, where ligand-bound ER functions as a key transcription factor
in various molecular estrogen-mediated activities in these tissues. Therefore, modulation of ER
expression levels is important in determining tissue-selective action of estrogen. Indeed, despite
its localization is several cell types, levels of ER expression is regulated by several factors,
which act as ER modulators. Effectors of chromatin structure, hormones,growth factors and a
variety of other agents have implicated multiple cellular mechanisms of regulation of ER
expression. For example, methylation of the ER gene down-regulates its expression, as does
MAPK kinase (MAPKK MEK), a downstream effector of growth factor signaling, and other
hormones such as androgens and progesterone (Pinzone, Stevenson et al. 2004).

Animal Models in Immune-Endocrine Studies

Experimental models for human diseases are of crucial importance not only to understand the
biological and genetic factors that influence the phenotypic characteristics of the disease but to
utilize as a basis for developing rational intervention strategies. Human use in biomedical studies
is limited by technical and ethical considerations. And although they have been instrumental in
increasing the understanding of the human immune system, studies in nonhuman primates are
constrained by high cost, limited availability, paucity of genetic models for human diseases, and
lack of genetically inbred strains suitable for stem cell or tissue transplantation. Over the past
century, the mouse has developed into the premier mammalian model system for genetic
research. Scientists from a wide range of biomedical fields have gravitated to the mouse because
of its close genetic and physiological similarities to humans, as well as the ease with which its
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genome can be manipulated and analyzed. Mice are suitable models for immunological studies,
as they demonstrate immunological similarities to humans. They display strong humoral and
cellular immune responses to experimental immunization (Gaines, Currie et al. 1965; Pinchuck
and Maurer 1965; Braley and Freeman 1971; Cerny, McAlack et al. 1971; Amsbaugh, Hansen et
al. 1972; Blomberg, Geckeler et al. 1972; Hellman, Fowler et al. 1972; Ghaffar and James 1973;
Heiniger, Taylor et al. 1975). Mice are extensively used in hormone-related studies, and are the
most common animal species used for immunological studies. Their immune systems are
extremely well-characterized, and biological reagents necessary to perform immunological
experiments are commercially readily available.

The use of rodent models in immune-endocrine studies is particularly advantageous because they
are short-lived and because of the availability of homogenous laboratory strains which permit
controlled research experiments. In addition, rodent transgenic models using genetic
manipulation of specific genes such as ERα and ERβ as well as gonadectomy models, have
contributed greatly to the current general understanding of endocrine function.

Summary and Study Objectives

Estrogen has been shown to play an important role in protection against osteoporosis in postmenopausal women (Turner, Riggs et al. 1994), in the prevention of coronary heart disease
(Iafrati, Karas et al. 1997), and in the maintenance of cognitive function (Tang, Jacobs et al.
1996). In addition to the positive effects reproductive and non reproductive tissues, estrogen
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plays an important role in the development of uterine cancers and has been implicated in the
development of breast cancer (Jordan and Murphy 1990; McKenna, Xu et al. 1999; Peto,
Boreham et al. 2000).
The conflict between the positive and negative effects of estrogen has fueled a search for
selective estrogen receptor modulators (SERMs) for use in hormone replacement therapies
(HRT) that possess the capability of harnessing the tissue-selective beneficial effects of estrogen
while lacking adverse activities in breast and uterus. In addition to their use in HRT, SERMs
have been studied for their potential therapeutic advances in other areas of clinical practice.
In males, estrogen is produced in small quantities as result of biosynthetic conversion from
testosterone and a byproduct of other pathways. In females, estrogen levels fluctuate over a
lifetime, from birth, through puberty, pregnancy, and finally menopause. These varying levels
have a dramatic impact on health and immunity at a cellular level.
The aim of the present dissertation is to further characterize the immunomodulatory role of
estrogen using an in vivo vaccine model. This model is designed to determine the influence of
estrogen on vaccine responses to commonly administered human vaccine formulations in mice.
We have shown that (1) estrogen influences not only specific antibody responses in vaccinated
mice, but (2) the mechanism of this effect may occur at the level of innate immunity during
initial antigen encounter by macrophage TLR2 and (3) that estrogen influences other important
macrophage functions that lead to specific adaptive response by modulating FcγR gene
expression and function. Therefore, we show that estrogen manipulation in mice impacts both
the innate and adaptive immune functions.
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Though estrogen’s immunomodulatory role has been documented in many different systems, it is
still unclear how estrogen may influence induction of immunity through vaccination. Beginning
to understand the gender differences and the general role of sex hormones in vaccine responses
in human and experimental animal models may be the basis for achieving improved vaccine
efficacy in certain target populations based on sex, age and immune status as well as provide
new perspectives with which to design future vaccines against infectious diseases.
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CHAPTER 2
Experimental Methods

Animals
Female Balb/c mice were housed in standard conditions with food and water provided ad libitum
and a constant light cycle of 12 hours (lights on from 8:00 to 20:00). Male mice were co-housed
and served as controls. Female and male mice were fed isoflavone-free, soy-free casein diet (Lab
Diet, Richmond, IN). All animals were housed and subjected to experimental procedures in
accordance to protocols approved by the appropriate institutional review committee.

Ovariectomy
At 6-8 weeks of age, mice were anesthetized with 5% isoflurane gas in 100% oxygen. Ovaries,
oviducts and tips of the uterine horns were bilaterally removed via two dorsal intraperitoneal
incisions. The incisions were repaired with suture and skin staples. Sham ovariectomies were
performed identically except the ovaries were not removed.

Estrogen replacement
Estrogen replacement by subcutaneous implantation of 17-β estradiol (E2) pellets was performed
as follows: sterile E2 pellets were inserted through a subcutaneous tunnel made between the
scapulae. Mice were given a single (5 mm) subscapular Silastic implant (1.02 mm ID×2.16 mm
OD) containing either E2 diluted 1:1 with cholesterol (Sigma- Aldrich Corp., St. Louis, MO) or
cholesterol only. This pellet size yields E2 concentrations of 85–100 pg/ml, similar to that of
intact mice in proestrus (Wersinger, Haisenleder et al. 1999).
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Estrogen replacement through the drinking water was performed as follows: treated water was
prepared as previously described (Wersinger, Haisenleder et al. 1999), by diluting stock
solutions of E2 in 100% ethanol to solubilize. Solubilized estrogen was added to drinking water
to produce a final concentration of 1000 nM, as previously described (Mobbs, Cheyney et al.
1985; Wersinger, Haisenleder et al. 1999). The final concentration of ethanol was 0.1%. No
adverse effects of this concentration of ethanol or estrogen were reported (Wersinger,
Haisenleder et al. 1999).

Isolation of peritoneal macrophages
Prior to euthanization, mice were each injected intraperitoneally with 1 ml 3% sterile Brewer’s
thioglycollate medium. Five days later, mice were killed by exsanguination under isofluorane as
well as by cervical dislocation and a midline incision was made with a pair of sterile scissors.
After retraction of abdominal skin, 10 ml sterile cold PBS was injected through peritoneal wall.
Mice were gently agitated to dislodge cells bound within the peritoneal cavity. Peritoneal fluid
was then taken slowly with a yield of 8-10 ml total volume. Cell suspension was washed twice
with PBS, counted, suspended (1 x 106 cells/ml) in complete DMEM media and cultured for 2 h
at 37°C and 5% CO2. Non-adherent cells were rinsed with PBS and the adherent cells were kept
in wells to be directly lysed for RNA extraction (see below).

Splenocyte and splenic macrophage isolation
Spleens were removed aseptically and placed into 50-ml conical tube containing cold DMEM
medium. The spleens were then gently pressed through a 70 um cell strainer (BD Falcon) using a
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10 ml syringe plunger to produce single-cell suspension, and centrifuged at 2000 RPM, at 4°C
for 10 min. The erythrocytes were lysed with RBC lysis buffer (Sigma). The remaining cells
were then washed, counted, and suspended (1 × 107 cells/ ml) in DMEM medium and incubated
in 24-well plates. After 2 h of incubation (37°C at 5% CO2), non-adherent cells were removed,
and the adherent cells were kept in wells to be directly lysed for RNA extraction (see below).

Detection of specific antibody responses
Enzyme-linked immunosorbant assay (ELISA) was used to detect specific antibody responses.
Micro-titer wells were coated with the antigen, diluted in coating buffer (KPL, Inc.,
Gaithersburg, MD), in a volume of 50ul/well. Coated plates were incubated overnight at 4ºC. To
block nonspecific binding sites, wells were incubated for 30 min at 37ºC with 200ul/well PBS
containing 5% fetal calf serum (FCS-PBS) (Atlanta Biologicals, Lawrenceville, GA). Plates were
washed three times with PBS containing 0.05% Tween-20. To generate titration curves, serum
samples were tested by preparing two-fold serial dilutions (1:50-1:25600). Samples were added
to triplicate wells in a volume of 50ul/well, and incubated overnight at 4ºC. After washing three
times with PBS containing 0.05% Tween-20, wells were incubated with HRP-labeled anti-mouse
IgG or IgG+A+M (KPL) for 1 hr and 15 min at 37ºC. Wells were washed and then incubated
with 50ul/well ABTS/H2O2 (KPL) substrate for 10 min at room temperature, followed by
addition of 50ul/well stop solution (KPL). Optical density (OD) values were assessed at 405 nm
using a PowerWave HT plate reader (BioTek Instruments, Inc., Winooski, VT).
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Detection of total immunoglobulin production
Total immunoglobulin (Ig) production was assessed by ELISA according to methods similar to
those described above, with the following exceptions. Micro-titer plates were coated with
unlabeled goat anti-mouse IgG+IgA+IgM (KPL). Individual serum samples were titrated by
preparing 4-fold serial dilutions and added to triplicate wells. Plates were incubated overnight at
4 ˚C, washed as described above and incubated with HRP-labeled goat anti-mouse
IgG+IgA+IgM (KPL) for 1 h at 37 ˚C.

Detection of IgG1/ IgG2a responses
To determine the effects of estrogen on IgG1/IgG2a production, ELISA was used according to
methods similar to those described above, with the following exceptions. Plates were coated with
purified antigen depending on the vaccine administered. Individual serum samples were diluted
at 1:100 and added to triplicate wells. Plates were incubated overnight at 4 ºC, washed and
incubated with HRP-labeled goat anti-mouse IgG1 or HRP-labeled goat anti-mouse IgG2a
(KPL) for 1 h at 37 ˚C.

RNA extraction, RT-PCR and real time PCR
Total RNA was isolated using the RNeasy MiniKit (Qiagen, Valencia CA) from splenic
macrophages and thioglycollate-elicited peritoneal macrophages according to manufacturer’s
instructions. For plate-adhered macrophages, cells were lysed directly in wells of microplate.
RNA samples were quantified by spectrophotometric analysis and/or quantification by gel
electrophoresis prior to cDNA synthesis. Total RNA was reverse transcribed into cDNA using
the First Strand cDNA Synthesis Kit for RT-PCR where AMV reverse transcriptase synthesizes
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the new cDNA using random primers according to conditions provided by the manufacturer
(Roche Molecular Biochemicals, Indianapolis, IN). cDNA synthesis reactions were performed
with approximately 1ug of total RNA using 4 ug (0.08 A260 units) Random Primer p(dN)6,
10mM of each dNTP, 20 units AMV reverse transcriptase, 50 units RNase Inhibitor and 1 X
reaction buffer in a final volume of 20ul. cDNA reactions were incubated at 25° C for 10 min,
then at 42° C for 60 min, according to manufacturer’s instructions.
Amplification of the following target genes were performed by real time PCR using TaqMan
Gene Expression Assays (Applied Biosystems): TLR2, TLR4, FcγRI, FcγRIIB, FcγRIIIA, ER-α.
Realtime PCR was performed in a total volume of 25 ul with the following components: 1 X
TaqMan Gene Expression Master Mix, 1 X target gene primer/probe mix and 1 X endogenous βactin gene primer/probe mix (Applied Biosystems). Realtime PCR was performed in an ABI
PRISM 7700 Sequence Detection System thermal cycler (PE Applied Biosystems, Foster City,
CA) to quantify target genes. Cycle parameters were 50° C for 2 min to activate UNG, 95° C for
10 min to activate Taq, followed by 40 cycles of 95° C for 15 sec and 60° C for 1 min. The fold
change of target gene mRNA was expressed as 2

–ΔΔCt

(ΔCt = the difference in threshold cycles

for the test gene and β-actin, ΔΔCt = the difference between the experimental and control mice,
or as indicated).
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CHAPTER 3
Estrogen-Induced Modulation of Anti-Tetanus Toxoid Antibody Responses in a Murine
Model

SUMMARY
It is well established that sex hormones influence the immune response. Estrogen modulates
lymphocyte activity and cytokine production and enhances the antibody response to several
immunogens. Therefore, estrogen may influence the antibody response to specific vaccine
preparations. To test this hypothesis, we used a model consisting of female mice subjected to
ovariectomy and immunized with tetanus toxoid (TT) in two experimental protocols, differing
for modality of estrogen replacement (either subcutaneous pellet administration or administration
in drinking water). In each protocol, mice were assigned to one of three experimental groups.
The first group of mice, designated OVEX-E2, was ovariectomized and subjected to estrogen
(E2) replacement. The second group, designated OVEX group, was ovariectomized but received
no estrogen replacement. The third group remained intact. In the first experimental protocol
(pellet-E2), mice were either immunized subcutaneously (SC), or were unvaccinated. In the
second immunization protocol (drinking water-E2), mice were immunized either subcutaneously
(SC) or intramuscularly (IM) or were unvaccinated. Results from both studies show that, in
general, E2 replacement results in higher anti-TT antibody responses. In the drinking water-E2
groups, mice vaccinated by the IM route produced significantly higher anti-TT IgG levels than
mice vaccinated by the SC route after the third vaccination dose. OVEX-E2 mice produced
significantly higher anti-TT IgG levels than OVEX and intact mice when vaccinated either IM or
SC. The anti-TT IgG responses were predominantly of the IgG1 isotype in all groups of mice.
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Together, these results show that estrogens may influence the murine antibody response to
vaccines routinely administered to human populations.

INTRODUCTION

The major functions of sex hormones relate to sexual differentiation and reproduction. Sex
hormones can also interact with the immune system, thus causing a gender dimorphism in
immune function. This dimorphism was initially demonstrated by the observation that females
produce higher immunoglobulin levels and mount stronger immune responses to immunization
or infection than males (Verthelyi 2001; Wierman 2007). Females are also known to show
increased susceptibility to autoimmune diseases (Da Silva 1999; Whitacre, Reingold et al. 1999;
Verthelyi 2001; Whitacre 2001).

Estrogens can modulate the immune system through direct interaction with estrogen receptors
present in immune cells, including lymphocytes, macrophages, dendritic cells (DCs) and natural
killer cells (Tornwall, Carey et al. 1999; Curran, Berghaus et al. 2001; Benten, Stephan et al.
2002; Phiel, Henderson et al. 2005) and enhance differentiation and antigen presentation by
macrophages and DCs (Tornwall, Carey et al. 1999). Elevated levels of estrogen promote
polyclonal B cell activation (Weetman, McGregor et al. 1981; Grimaldi, Michael et al. 2001) and
increase production of IgG, including IgG anti-dsDNA by lymphocytes from patients with
systemic lupus erythematosus (Kanda and Tamaki 1999). In pregnancy, lymphopoeisis is
reduced, as demonstrated by a reduction in the number of B cell precursors in the bone marrow.
This reduction appears to be the result of elevated estrogen levels, which impair progression
from the pro-B cell stage to the early pre-B cell stage (Smithson, Beamer et al. 1994; Medina,
47

Garrett et al. 2001). Estrogen may affect humoral immunity via a thymic route of action. For
example, in vitro stimulation of B cells with ovarian steroid hormones enhances antibody
secretion only in the presence of CD8+ T cells (Lu, Abel et al. 2002).

Estrogen has modulatory effects on both TH1 and TH2 type cells. Estrogen is shown to inhibit the
production of TH1 pro-inflammatory cytokines, such as IL-12, TNF-α and IFN-γ, whereas it
enhances the production of TH2 anti-inflammatory cytokines, such as IL-10, IL-4, and TGF-β
(Giltay, Fonk et al. 2000; Harris, Feldberg et al. 2000; Angele, Knoferl et al. 2001; KarpuzogluSahin, Zhi-Jun et al. 2001; Kovacs, Duffner et al. 2004; Salem 2004; Gourdy, Araujo et al.
2005). These modulatory effects may partially explain why estrogen suppresses TH1-mediated
autoimmune diseases, such as rheumatoid arthritis, experimental autoimmune encephalomyelitis
and multiple sclerosis (Josefsson and Tarkowski 1997; Bebo, Schuster et al. 1999; Ostensen
1999; Matejuk, Adlard et al. 2001; Voskuhl and Palaszynski 2001; Matejuk, Dwyer et al. 2002;
Fu, Jiang et al. 2005; Janssen, Tabeta et al. 2006), and exacerbates TH2-mediated diseases, such
as systemic lupus erythematosus and Sjorgen’s syndrome (Roubinian, Talal et al. 1978; Ralston,
Russell et al. 1990; Buyon 1998; Ostensen 1999; Bynoe, Grimaldi et al. 2000; Elenkov, Wilder
et al. 2001).

Further evidence of estrogen-mediated effects on TH1/TH2 cells is provided by results from
studies carried out with pregnancy and menopause models. During the luteal phase of the ovarian
cycle, when estrogen levels peak, the immune response shifts to favor a TH2-type response, as
reflected by increased IL-4 and TGF-β levels (Faas, Bouman et al. 2000; Ayatollahi,
Geramizadeh et al. 2007). Pregnancy is considered to be a TH2-type phenomenon, which might
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play a critical role in maternal acceptance of the fetus (Lin, Mosmann et al. 1993; Wegmann, Lin
et al. 1993; Piccinni, Scaletti et al. 2000; Laird, Tuckerman et al. 2003). Pregnancy results in
suppression of TH1-type responses, which may partially explain the spontaneous remission and
post-partum relapse of T-cell-mediated autoimmune diseases, such as multiple sclerosis and
rheumatoid arthritis, observed in women (Fu, Jiang et al. 2005). In menopausal women, there is
an increase of TH1 cytokines relative to TH2 cytokines. Hormone replacement therapy prevents
the TH1 cytokines increase, thus restoring the TH1/ TH2 balance (Kamada, Irahara et al. 2001).

Due to the well-established role that estrogen plays in modulating the immune system, it is
reasonable to postulate that estrogen influences the immune response to vaccines. To test this
hypothesis, we have compared the murine antibody responses produced in presence or absence
of estrogen against the currently available TT vaccine.

MATERIALS & METHODS
Animals
For the entire study, female BALB/c mice (Charles River Laboratories, Inc., Wilmington, MA)
were used. The study consisted of two experimental protocols. In the first protocol, animals
received E2 as pellet implantation (pellet-E2 replacement). In the second protocol, animals
received E2 in the drinking water (oral-E2 replacement). For both experimental protocols, mice
were divided into 3 groups. The first group of mice, designated OVEX-E2 group, was
ovariectomized and subjected to estrogen replacement. The second group, designated OVEX
group, received no estrogen replacement. The third group remained intact. Table 3.1 and 3.2
show the experimental designs for both protocols. Mice were ovariectomized at 8 weeks of age.
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Designated mice were anesthetized with 5% isoflurane gas in 100% oxygen, and their ovaries,
oviducts and tips of the uterine horns were bilaterally removed via two dorsal incisions.
Immediately following surgery, mice in the OVEX-E2 group started E2 replacement. Seven days
following surgery, mice were given the first vaccine injection. Blood was collected from each
mouse prior to and following hormone manipulation and immunization. To test for uterotrophic
responses, uteri were removed and weighed at termination. All animals were housed and
subjected to experimental procedures in accordance to protocols approved by the appropriate
institutional review committee.

Pellet-E2 replacement and immunization
Sterile E2 pellets were inserted during ovariectomy through a subcutaneous tunnel made between
the scapulae. Mice were given a single (5 mm) subscapular Silastic implant (1.02 mm ID×2.16
mm OD) containing either E2 diluted 1:1 with cholesterol (Sigma-Aldrich Corp., St. Louis, MO)
or cholesterol only. This pellet size yields E2 concentrations of 85–100 pg/ml, similar to that of
intact mice in pro-estrus (Wersinger, Haisenleder et al. 1999). Mice were immunized with a
primary (day 0) and secondary (day 28) dose of human TT vaccine, alum adsorbed (SanofiAventis, Bridgewater, NJ). The OVEX and control groups received a third dose at day 125. All
injections were given subcutaneously on the dorsal side of the mice. They received 0.05 ml,
equal to one tenth the human immunizing dose, given in 0.2 ml saline (0.15 M NaCl), for a total
dose volume of 0.250 ml. The immunization and blood collection schedule is shown
schematically in Figure 3.1 A.
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Table 3.1. Pellet- E2 Study: Experimental Design
Hormone group

Treatment

Vaccine group

OVEX

Placebo pellet

TT

11

Placebo pellet

Unvaccinated

11

E2 pellet

TT

11

E2 pellet

Unvaccinated

11

none

TT

11

none

Unvaccinated

11

OVEX + E2

Sham OVEX (intact)

No. of mice

Table 3.2. Oral-E2 Study: Experimental Design
Hormone group

Treatment

OVEX

none

OVEX + E2

Sham OVEX (intact)

1000 nM E2

none

Vaccine
group

Route of
administration

No. of
mice

TT

IM

11

TT

SC

11

Unvaccinated none

10

TT

IM

11

TT

SC

11

Unvaccinated none

10

TT

IM

11

TT

SC

11

Unvaccinated none

10

TT, tetanus toxoid; SC, subcutaneous; IM, intramuscular
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Oral-E2 replacement and immunization
E2 was administered in the drinking water. E2-treated water was prepared as previously
described by diluting stock solutions of E2 (Sigma- Aldrich Corp., St. Louis, MO) in 100%
ethanol to solubilize. Solubilized estrogen was added to drinking water to produce a final
concentration of 1000 nM, as previously described (Levin-Allerhand, Sokol et al. 2003;
Fernandez and Frick 2004). The final concentration of ethanol was 0.1%. No adverse effects of
this concentration of ethanol or estrogen were reported. The concentration administered results in
an ingested dose of approximately 50-70 kg/ug per day, corresponding to about 15 pg/m (LevinAllerhand, Sokol et al. 2003; Fernandez and Frick 2004). Estrogen levels during the estrus cycle
in mice typically range from 10-40 pg/ml (Nelson, Karelus et al. 1995). A 1000 nM dose in the
drinking water was previously shown to result in uterine weights that were significantly higher
than those of control mice, yet not significantly different from those of mice given either 1500
nM or 2500 nM doses, implying a uterotrophic response that plateaus with increasing E2 doses
(Fernandez and Frick 2004). Mice were immunized with a primary (day 0), secondary (day 28)
and tertiary (day 84) dose of human TT vaccine. Similarly to animals in the pellet-E2 protocols,
mice receiving subcutaneous injections were given 0.05 ml in 0.2 ml saline (0.15 M NaCl), for a
total dose volume of 0.250 ml, injected on the dorsal side of the mouse. In mice receiving
intramuscular injections, 0.025 ml was injected into each calf muscle for a total dose volume of
0.05 ml. The doses administered are equal to one tenth the human immunizing dose. The
immunization and blood collection schedule is shown schematically in Figure 3.1 B.
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A

OVX/ E2
treatment

TT Immunization
1st Dose

-8

-5 0

2nd Dose

14

21

3rd Dose

35

84

4th Dose

98

223

Terminal
bleed/
sacrifice

B

290

~10 months

Figure 3.1. E2-TT Study: Hormone treatment and vaccination schedule.
Mice were ovariectomized and mice designated to receive E2 replacement were A, implanted
with pellets containing E2 or B, given E2 orally through the drinking water. Mice were
vaccinated on Day 0 with TT. Booster doses are indicated by large arrows. On the days of
sacrifice, uteri were removed and weights measured to confirm uterotrophic activity. The small
arrows indicate days of blood collection for determination of CFP-specific antibody responses.
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Detection of anti-TT toxoid antibody responses
Anti-TT antibody responses were assessed by ELISA. Micro-titer wells were coated with
purified TT antigen (Sanofi-Aventis) diluted in coating buffer (KPL, Inc., Gaithersburg, MD).
Negative control wells were coated with purified baculovirus-recombinant glycoprotein I from
herpes B virus (kindly provided by Dr. Ludmilla Perelygina). To block nonspecific binding sites,
wells were incubated for 30 min at 37ºC with PBS containing 5% fetal calf serum (FCS-PBS,
Atlanta Biologicals, Lawrenceville, GA).

Serum samples were diluted in two-fold serial

dilutions (1:50-1:25600), added to triplicate wells, and incubated overnight at 4ºC. After washing
with PBS containing 0.05% Tween-20, wells were incubated with either HRP-labeled goat antimouse IgM (KPL) or HRP-labeled goat anti-mouse IgG (KPL) for 1 hr and 15 min at 37ºC.
Wells were washed and then incubated with ABTS/H2O2 (KPL) substrate for 10 min at room
temperature, followed by addition of stop solution (KPL). Optical density (OD) values were
assessed at 405 nm using a PowerWave HT plate reader (BioTek Instruments, Inc., Winooski,
VT). Endpoint titers were defined as the highest serum dilution that yielded an OD value greater
than or equal to 3 times the mean values of the same serum samples tested against the negative
control coat protein at a 1:50 dilution.

Determination of total immunoglobulin production
Total immunoglobulin (Ig) production was assessed by ELISA according to methods similar to
those described above, with the following exceptions. Micro-titer plates were coated with
unlabeled goat anti-mouse IgG+IgA+IgM (KPL). Individual serum samples were added to
triplicate wells. Plates were incubated overnight at 4 ˚C, washed and incubated with HRP-labeled
goat anti-mouse IgG+IgA+IgM (KPL) for 1 h at 37 ˚C.
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Determination of IgG1/IgG2a responses
To determine the effect of estrogen on IgG1/IgG2a production, ELISA was used according to
methods similar to those described above, with the following exceptions. Briefly, plates were
coated with purified TT antigen (Sanofi-Aventis). Individual serum samples were diluted at
1:100 and added to triplicate wells. Plates were incubated overnight at 4 ºC, washed and
incubated with HRP-labeled goat anti-mouse IgG1 or HRP-labeled goat anti-mouse IgG2a
(KPL) for 1 h at 37 ˚C.

Determination of natural autoantibody (NAA) production
ELISAs were done to assess NAA levels in mice according to methods described above. Briefly,
plates were coated with 4 ug/ml calf thymus extract (CTE) (Immunovision). Individual and
pooled serum samples were diluted at 1:200 and added to triplicate wells. Plates were incubated
overnight at 4 ºC. Wells were incubated with HRP-labeled goat anti-mouse IgG+A+M (KPL) for
1 h at 37 ˚C.

Statistical analysis
The SPSS program (SPSS Inc, Chicago, Illinois) version 12 was used for statistical analysis.
Independent t-test was used to analyze group differences by immunization route. Analysis
among multi-group data was carried out using ANOVA, followed by Turkey's significant
difference test, or Tamhane's T2 test when the test of homogeneity of variances (Levene
Statistic) indicated that the variance between the groups was not equal. Differences among
groups were considered significant if p <0.05.
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RESULTS
As mentioned above, we used two different experimental protocols for this study. In the first
protocol, mice received pellet-E2 replacement, whereas in the second protocol animals received
oral-E2 replacement. Continuous release hormone pellets have been used and described
extensively in the literature. In the present study, we used silastic pellets containing amounts of
E2 previously shown to result in physiological levels of plasma E2 in balb/c mice (Wersinger,
Haisenleder et al. 1999). However, we observed that within the third week of our study, mice
receiving pellet-E2 delivery began to develop reddening and swelling of the vulva and perineum,
eventually developing urinary retention and subsequent dribbling which resulted in scalding
around the genital area. Therefore, OVEX-E2 mice were sacrificed at day 42. Continuous
release of the E2 may not be suitable for chronic treatment. Indeed, urinary retention leading to
subsequent death is documented in ovariectomized mice receiving chronic, subcutaneous
estrogen replacement, which is not documented in hamsters or rats (Levin-Allerhand, Sokol et al.
2003).

In the second experimental protocol, we used oral administration through the drinking water as
method of delivery. This method of E2 replacement was chosen for various reasons. First of all,
it is safer because it results in uterotrophic responses, yet does not cause urine retention as seen
with continuous release E2 capsules (Gordon, Osterburg et al. 1986; Levin-Allerhand, Sokol et
al. 2003). Therefore, it is a more appropriate method for long-term delivery, as needed for
measuring vaccine responses. Second, oral E2 delivery has been demonstrated to induce
physiological responses in three different target tissues, including the vagina, uterus and pituitary

56

(Gordon, Osterburg et al. 1986). Finally, as a result of circadian patterns in drinking behavior,
oral E2 administration does not produce chronically elevated levels of circulating E2. Rather,
elevations occur during peak nocturnal drinking periods, and levels return to baseline
approximately 15 hours later (Gordon, Osterburg et al. 1986). Therefore, this method results in
cyclic estrogen levels that mimic natural E2 fluctuations during the estrus cycle.

Uterine weight
Uterine weights were measured and compared between the groups to determine the uterotrophic
response to E2 delivery. As expected, in the pellet-E2 delivery group, OVEX-E2 mice had
uterine weights approximately 3.1 and 1.3 times higher than OVEX and intact mice respectively.
The uterine weights of OVEX mice were 2.4 times lower than those of the intact mice (p <
0.001) (Table 3.2). Similarly, in the oral E2-delivery group, OVEX-E2 mice had uterine weights
approximately 2.5 and 1.4 times higher than the OVEX and intact mice, respectively (p < 0.001).
The uterine weights of OVEX mice were 1.7 times lower than those of the intact mice (p <
0.001).

Pellet-E2 Experimental Protocol

Anti-TT antibody responses
To test the hypothesis that estrogen influences the antibody response to vaccines, groups of mice
were ovariectomized, subjected to estrogen replacement and immunized with the TT vaccine.
The IgM and IgG or IgG+A+M anti-TT responses produced by these groups of mice (OVEXE2) were compared to the same response generated in OVEX mice and in control mice. OVEX-
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E2 mice received a total of two immunizations (day 0 and 28), whereas OVEX and control mice
received a total of three immunizations (day 0, 28 and 125). Serum samples obtained from all
mice on day 42 were tested for IgM, IgG and IgG+A+M anti-TT responses by ELISA. Serum
samples obtained from the OVEX and control groups on day 139 were tested for anti-TT
responses. At day 42, the IgM anti-TT responses did not differ significantly between the OVEXE2 and the other two groups of mice (data not shown), whereas OVEX-E2 mice produced
significantly higher IgG and IgG+A+M TT-specific antibody levels than OVEX and control
mice (p > 0.05) (Figure 3.2 and Figure 3.3). Antibody responses did not differ significantly
between the OVEX and control groups. Even after receiving a third dose of TT vaccine on day
125, OVEX and control mice showed no significant differences in long-term specific IgG
antibody response (p > 0.05) (Figure 3.4). Sera from OVEX-E2 mice were not available for
comparison due to termination of this group after the second immunization dose. All samples
were also tested against herpes B virus glycoprotein I as a negative control, which resulted in
IgG OD values that were below 0.1. These were used to generate endpoint titers for the same
data.

Anti-TT IgG1 antibody responses
To assess whether or not E2 treatment influenced expression of the IgG1 subclass, which is
known to be the predominant subclass produced by mice in response to TT vaccination (Gupta
and Siber 1994), TT-specific IgG1 and IgG2a responses were determined. Figure 3.5 shows that,
according to what observed for overall IgG responses, OVEX-E2 mice produced the highest
levels of TT-specific IgG1 following vaccination (p < 0.01), thus confirming that E2 replacement
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Table 3.3. Uterotrophic responses in OVEX-E2, OVEX and intact mice.
Mice were sacrificed at day 227 and uteri were removed and weighed. Weights represent mean
values of 32 mice ± SD (OVEX-E2 and OVEX) or 30 mice ± SD (intact). 1significant difference
in weight from intact and OVEX-E2 mice (p < 0.001). 2Significant difference in weight from
OVEX and OVEX-E2 mice (p < 0.001).

Hormone group

Uterine weight (g)
Pellet E2 Delivery

Oral E2 Delivery

OVEX

0.044 ± 0.03 1

0.055 ± 0.02 1

INTACT

0.105 ± 0.08 2

0.096 ± 0.06 2

0.138 ± 0.02

0.136 ± 0.04

OVEX-E2
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Figure 3.2. The effect of estrogen on TT-specific IgG and IgG+A+M antibody responses.
A, IgG+A+M and B, IgG (γ) responses against tetanus toxoid vaccination in mice 14 days after
the second immunization (day 42). Binding curves represent 2-fold serial dilutions of sera.
Curves represent mean values obtained from 11 mice per group. Curves represent data from the
vaccinated groups, bars represent data from the unvaccinated groups to show background
binding.
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Figure 3.3. Anti-TT IgG and IgG+A+M titers in OVEX-E2, OVEX and intact mice.
A, IgG+A+M and B, IgG (γ) responses against tetanus toxoid vaccination in mice 14 days after
the second immunization (day 42). Endpoint titers were calculated as 3 times the mean of the
average OD of the negative control at a 1:50 dilution. Data shown represents the mean titers of
11 mice per group. * p < 0.05, ** p < 0.01.
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Figure 3.4. Longterm antibody responses.
Sera from OVEX and intact mice were tested for anti-TT IgG (γ) the day of (day 125) and 14
days after (day 139) the third immunization was administered to determine longterm responses.
Endpoint titers were calculated as 3 times the mean of the average OD of the negative control at
a 1:50 dilution. Data shown represents the mean titers of 11 mice per group ± SEM.
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Figure 3.5. The effect of estrogen on TT-specific IgG1 production.
Individual mouse samples at day 42 were tested at 1:200 dilution. The concentration of IgG1 in
serum was determined against a standard curve using purified mouse myeloma IgG1. OVEX-E2
mice have higher levels of anti-TT IgG1 compared to OVEX and intact mice (p < 0.01).
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leads to production of higher TT-specific responses. TT-specific IgG1 levels did not differ
between OVEX and intact mice, indicating the presence of a stronger Th2 response in the
OVEX-E2 mice. TT-specific IgG2a was not detected in any of the mice (data not shown).

Oral-E2 Experimental Protocol

Anti-TT IgG responses
To test the hypothesis that estrogen influences the antibody response to vaccines, groups of mice
were ovariectomized, subjected to estrogen replacement and immunized with the TT vaccine.
The anti-TT response produced by this group of mice (OVEX-E2) was compared to the same
response generated in OVEX and in intact mice. All mice received a total of three immunizations
(day 0, 21 and 84). Serum samples obtained from all mice at day 0 as well as 14 days after the
second and third immunizations (days 35 and 98, respectively) were tested for anti-TT IgG
responses by ELISA. At day 35, OVEX-E2 and intact mice produced significantly higher antiTT IgG levels than OVEX mice (p <0.05) when vaccinated SC (Figure 3.6 and Figure 3.7).
OVEX-E2 mice produced significantly higher anti-TT IgG levels than OVEX and intact mice
when vaccinated IM (p < 0.01) (Figure 3.6 A). At day 98, OVEX-E2 produced significantly
higher anti-TT IgG levels than the OVEX and intact mice when vaccinated either IM or SC (p <
0.05) (Figures 3.6 B and Figure 3.7). For both day 35 and 98, mice vaccinated IM produced
significantly higher anti-TT IgG levels than mice vaccinated SC (p < 0.05). All samples were
also tested against herpes B virus glycoprotein I as a negative control, which resulted in IgG OD
values that were below 0.1. These were used to generate endpoint titer values for the same data,
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shown in Figure 3.7. Unvaccinated animals showed similar low OD values compared with
vaccinated animals (Figure 3.6).

Total Ig and IgG1/IgG2a responses
As already mentioned, it is known that estrogen may increase polyclonal B cell activation
(Kanda and Tamaki 1999). To determine whether or not the increased anti-TT antibody levels
detected in the OVEX-E2 mice as compared to the OVEX and intact mice were due to specific
anti-TT responses and not just to increased total Ig production, total Ig levels were tested in
serum samples from all mice. These levels are not significantly different between groups (p >
0.05) (Figure 3.8). These results confirm that OVEX-E2 mice produce higher levels of specific
anti-TT antibody responses. To assess whether or not E2 treatment influenced expression of the
IgG1 subclass, TT-specific IgG1 and IgG2a responses were determined. Figure 3.9 shows that,
according to what observed for overall IgG responses, OVEX-E2 mice produced the highest
levels of TT-specific IgG1 following vaccination (p < 0.05), thus confirming that E2 replacement
leads to production of higher TT-specific responses. This effect was consistent whether mice
were vaccinated SC or IM. TT-specific IgG1 Levels did not differ between OVEX and intact
mice, indicating the presence of a stronger Th2 response in the OVEX-E2 mice. TT-specific
IgG2a was not detected in any of the mice (data not shown).

Natural autoantibody (NAA) levels
NAA are found in the serum of healthy individuals in the absence of infection or immunization.
Unlike specific, they do not undergo somatic hypermutation. As a result, they possess germline
specificity and are polyreactive to conserved structures. Although their function is not clear,

65

Figure 3.6. The effect of estrogen and route of administration on TT-specific IgG responses
(next page).
Sera obtained 14 days after the second immunization (day 35) and 14 days after the third
immunization (day 98) were tested fot anti-TT IgG. Binding curves and bars represent 2-fold
serial dilutions of sera from TT-vaccinated and unvaccinated mice, respectively. Data shown
represents the mean ± SEM of 11 mice per group. At day 35, OVEX-E2 and intact mice had
significantly higher anti-TT IgG levels than OVEX mice when vaccinated SC (p < 0.05) (A).
OVEX-E2 mice have significantly higher anti-TT IgG levels than the OVEX and intact mice
when vaccinated IM (p < 0.01) (C). At day 98, OVEX-E2 mice have significantly higher anti-TT
IgG levels than the OVEX and intact mice when vaccinated either IM or SC (p < 0.05). Mice
vaccinated IM had significantly higher anti-TT IgG levels than mice vaccinated SC (p < 0.05).
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Figure 3.7. Anti-TT IgG titers in OVEX-E2, OVEX and intact mice.
Mice were vaccinated with TT either IM or SC and sera from days 0, 35 (14 days after the
second dose) and 98 (14 days after the third dose) were tested for anti-TT IgG (γ). Endpoint titer
was defined as 3 times the mean of the average OD of the negative control at 1:50 dilution. Data
shown represents the mean ± SD of 11 mice per group. * p < 0.05, ** p < 0.01 compared to
intact mice.
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Figure 3.8. The effect of estrogen on total immunoglobulin levels.

Mice were vaccinated with TT by A, SC, B, IM routes or were C, unvaccinated. Individual
mouse samples from day 98 were 2-fold serially-diluted to generate titration curves, and tested
for levels of serum IgG+A+M by ELISA. Data shown represents the mean ± SEM of 11 mice
per group. There are no significant differences between the 3 groups (p > 0.05).
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Figure 3.9. The effect of estrogen on TT-specific IgG1 production.
Individual mouse samples obtained at day 98 were diluted at 1:200 and tested for production of
anti-TT IgG1 by ELISA. The concentration of IgG1 in serum was determined against a standard
curve using purified mouse myeloma IgG1. OVEX-E2 mice have higher levels of anti-TT IgG1
compared to OVEX and intact mice when vaccinated either IM or SC (p < 0.01).
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NAA constitute a large fraction of serum immunoglobulin. Immuno-adsorption studies show
that up to 66% of IgG from healthy individual sera are auto-reactive. One theory is that NAA are
may play a role in the initial response to infection. To test whether vaccination or estrogen
influences NAA levels, sera from day 98 were tested for reactivity against CTE. CTE was used
to its high content of phylogenetically conserved structures and because of the nonspecific
binding property of the NAAs. E2-treated mice had significantly higher NAA levels as compared
to the OVEX and control mice.

To test whether vaccination or estrogen influences NAA levels, sera from day 98 were tested for
reactivity against CTE. CTE was used to its high content of phylogenetically conserved
structures and because of the nonspecific binding property of the NAAs. E2-treated mice had
significantly higher NAA levels as compared to the OVEX and control groups (p < 0.01),
whereas the OVEX and control groups did not differ (Fig. 3.10). This was consistent irrespective
of vaccination. When sera taken prior to OVEX and E2-delivery were tested, there were no
significant differences between any of the 3 groups (data not shown). Vaccination alone did not
influence NAA levels in any of the three groups.
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Figure 3.10. The effect of estrogen and vaccination on natural autoantibody levels.
Sera from TT-vaccinated and unvaccinated OVEX-E2, OVEX and intact mice at day 98 were
diluted at 1:200 and tested for levels of IgG+A+M against 4 ug/ml CTE. Bars represent mean ±
SD of 11 mice per group. * p < 0.05, ** p < 0.01 compared to intact mice.
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DISCUSSION

Results from several studies indicate that estrogen influences the immune response generated
against a variety of immunogens. However, no information is available on the effects of
estrogens on the immune response to specific vaccine preparations currently used in human
populations. Therefore, the present study was carried out to assess whether or not estrogen may
affect the antibody response to one of the currently available vaccines, i.e., the TT vaccine. TT
represents one component of combination vaccines that include other components, i.e., tetanus
toxoid, reduced diphtheria toxoid, acellular pertussis vaccine (Tdap); tetanus toxoid and
diphtheria toxoids vaccine (Td); and diphtheria toxoid, tetanus toxoid and acellular pertussis
vaccine (DTaP). These vaccines are recommended and routinely administered to humans for
either childhood or adolescent and adult immunization. Our results show that E2 replacement
results in the generation of higher anti-TT IgG responses for both routes of administration, SC
and IM. However, for all groups, IM-vaccinated mice produced overall higher anti-TT IgG
levels than did SC-vaccinated mice. In humans, these two routes of vaccine administration do not
appear to result in different immunogenicity profiles (Mark, Carlsson et al. 1999; Ruben,
Froeschle et al. 2001).

We used a uterine weight bioassay to confirm the efficacy of hormone treatment due to its welldescribed high sensitivity to low levels of estrogen treatment (Mobbs, Cheyney et al. 1985).
Results obtained by measurement of uterine weight confirmed the efficacy of hormone
replacement. The finding that no significant differences were detected in anti-TT antibody
responses between OVEX and intact mice after a third immunization dose, indicates that

73

endogenously cycling estrogen levels may not ultimately be sufficient to enhance humoral
responses to TT vaccination.

Consistent with the finding of increased anti-TT IgG production in the OVEX-E2 mice,
significantly increased levels of anti-TT IgG1 were observed in the OVEX-E2 mice as compared
to OVEX and intact mice. IgG2a and IgG1 are often used as indicators for the induction of
murine Th1 and Th2 responses, respectively, and the IgG1/IgG2a ratio can help to define the Tcell phenotype induced by vaccination(Coffman, Seymour et al. 1988). Indeed, bacterial protein
antigens administered in alum adjuvant, such as TT, are known to induce mostly IgG1 responses
(van der Giessen and Groenboer-Kempers 1976; Stevens, Dichek et al. 1983; Seppala and
Makela 1984; Rubin, Tang et al. 1986; Watt, Zardis et al. 1986; Grun and Maurer 1989; Comoy,
Capron et al. 1997; Cox 1997). Production of Th1 cytokines is augmented in women after
menopause.

HRT prevents this increase, thereby restoring the Th1/Th2 balance that is

implicated in inadequate immune responses and pathological conditions (Kamada, Irahara et al.
2001). However, in mice, E2 treatment results in increased IFN-gamma and decreased IL-4
production from in vitro antigen stimulated CD4+ T cells (Maret, Coudert et al. 2003). These
differences might be explained on the basis of a biphasic effect of E2, resulting in enhanced IFNgamma production at low E2 concentrations, but enhanced IL-10 production at higher E2
concentrations (Gilmore, Weiner et al. 1997; Correale, Arias et al. 1998; Beagley and Gockel
2003). Indeed, the dose of E2 replacement used in our study results in E2 levels that are
significantly higher than in the OVEX and intact mice, as demonstrated by significantly
increased uterine weights.
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Several recent studies have examined immune responses in different compartments of female
reproductive tract in response to immunization. Results from these studies show that E2 either
alone or in combination with progesterone not only influence immune responses in the female
reproductive tract, but also regulate susceptibility to infections (Crowley, Horner et al. 1997;
Martin, Nyange et al. 1998; Sonnex 1998; Kaushic, Zhou et al. 2000; Gillgrass, Fernandez et al.
2005; Gillgrass, Tang et al. 2005).

Little information exists regarding the role that estrogen plays in the systemic immune responses.
Results from earlier studies indicates that immunization with various T-dependent and Tindependent antigens, such as horse or goat erythrocytes and polyvinylpyrrolidone, respectively,
results in enhanced IgG and IgM titers in female mice as compared to male mice (Eidinger and
Garrett 1972). Others have demonstrated that females have stronger and longer lasting humoral
responses to bovine serum albumin compared to males (Terres, Morrison et al. 1968). Given the
hormonal differences between males and females, these observations are consistent with the
hypothesis that physiological levels of E2 enhance humoral immune responses to antigens.
Indeed, results from additional earlier studies show that female rats produce higher antifluorescein antibody titers than male rats and that, in OVEX rats, primary and secondary antifluorescein antibody responses are significantly reduced compared to sham OVEX controls
(Trawick and Bahr 1986; Erbach and Bahr 1991). Results from our study are in agreement with
the majority of these earlier findings, with the possible exception of the latter mentioned study.
Indeed, our results show no significant longterm differences between OVEX and intact mice at
day 98, with increased responses present only in the OVEX-E2 mice. Differences in animal
models (rats versus mice) and immunogen used may explain this discrepancy.

75

Clearly, additional studies are required to assess the influence of type, dose of antigen, adjuvant,
and additional routes of administration on the immune response elicited in presence or absence
of estrogen. Similarly, additional studies should include different doses of estrogens and different
times of estrogen treatment.

In conclusion, the results from our preliminary study show that

estrogen may enhance the antibody response to a commonly used vaccine and suggests
intriguing possibilities regarding the potential use of sex hormones as immunomodulators of the
immune response to specific vaccines. In addition, our results emphasize the importance of
taking into account the effects of estrogens in evaluating vaccine efficacy, especially in
menopausal women (subjected or not to hormone replacement therapy) which represent a major
subset of elderly individuals, a population known to exhibit a decreased response to vaccine
administration. The future understanding of the specific mechanisms at the basis of the estrogeninduced modulation of the immune response might lead to the design of novel prevention
strategies based on the use of vaccines.
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CHAPTER 4

Estrogen-Induced Modulation of Murine Macrophage Genes Involved in Innate and
Adaptive Immune Responses

SUMMARY
Macrophages play important roles in the immune response, as they are capable of not only
phagocytosis and destruction of foreign cells and debris but also acting as antigen presenting
cells. Thus they stand at the crossroads of innate and adaptive immunity. The key mechanisms
by which macrophages exert their effects depend on the expression and function of different
types of receptors. Toll-like receptors (TLRs) detect and bind directly to pathogenic ligands in
the microenvironment and are critical in the first line of defense against infection. Antibody-Fc
gamma receptors bind to antibodies-antigen complexes and are therefore involved in activation
of the adaptive immune response. We have examined the effects of estrogen on TLR2 and FcγR
gene expression from primary splenic and thioglycollate-elicited macrophages isolated from
female mice either ovariectomized only or overiectomized and given estrogen (E2) replacement
and intact mice. We found that TLR2, FcγRI and FcγRIII but not FcγRIIB gene expression is
greatly down-regulated in estrogen-replaced mice. When we compared intact female mice to
male mice, we found a clear gender dimorphism in expression of these genes. When immunized
with M. tuberculosis culture filtrate proteins containing TLR-inducing LAM, E2-replacement
enhanced specific antibody responses. On the other hand, E2-replacement down-regulated gene
expression while ovariectomy up-regulated expression. TLR and FcγR are co-expressed on
macrophages, where co-ligation leads to increased pro-inflammatory cytokine release. Since
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FcγRIIB gene expression was not affected by estrogen–replacement, this indicates that estrogen
enhances macrophage genes encoding receptors involved in activation of the immune system,
but not receptors involved in inhibition of the immune system. Altogether, our results suggest
that gender differences as well as varying levels of estrogen in females may differentially
influence immune function at the level of B cells and macrophages and that these differences
should be considered when designing vaccine strategies for different target populations subject to
endogenous or exogenous estrogen fluctuations.

INTRODUCTION

Macrophages play a significant role in host defense against infection. In innate immunty,
macrophages are phagocytic cells involved in the activation of the inflammatory response. In
adaptive immunity, macrophages are professional antigen-presenting cells which allow antigen
recognition by T lymphocytes resulting in the activation and specific effector functions that lead
to maximum antigen clearance. The critical functions of macrophages are mediated by various
types of receptors, whose expression and function contribute to pathogen clearance as well as
activation of adaptive responses necessary for long-term immunity. Macrophages express toll
like receptors (TLRs), which are considered to be the principal membrane signaling molecules
through which mammals sense infection. The innate immune response to bacterial infection is
triggered when TLRs located on the cell surface recognize bacterial components, as for example
lipopolysaccharide (LPS) and peptidoglycan (PGN), the major constituents of gram-negative and
gram-positive bacterial cell walls, respectively. Ligation of TLRs leads to signaling mediated by
the adaptor protein MyD88 and subsequent NF-κB activation, ultimately resulting in expression
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of co-stimulatory molecules as well as pro-inflammatory cytokines including IL-6, IL-12 and
TNF-α, which are important in activation of B and T cells and differentiation of T helper
subsets.

Macrophages also express opsonic phagocytic receptors, including receptors for the Fc portion of
immunoglobulin G (IgG), the Fcγ receptors (FcγR), which allow effector cells to recognize and
bind immune IgG complexes rapidly and efficiently. FcγR cross-linking results in internalization
of immune complexes by phagocytosis/endocytosis, antigen presentation, antibody-dependent
cellular cytotoxicity (ADCC) and the release of inflammatory mediators. Thus, the functions of
TLRs and FcγR are the most critical for macrophages, as they are necessary for not only for
activation during the initial response to infection but also for antigen presentation and signaling
to activate the adaptive immune response.

Macrophage functions may be regulated to a large extent by sex hormones. Estrogen, a known
immunomodulator, can act directly on monocytes and macrophages, decreasing the production
of proinflammatory cytokines such as IL-1, IL-6 and TNF-α. Evidence for estrogen modulation
of TLRs has been documented within the female reproductive tract (FRT). TLRs and estrogen
receptors (ER) are co-expressed abundantly in uterine and vaginal mouse epithelial cells (Soboll,
Shen et al. 2006). In endometrial epithelial and stromal cells, TLR2, 3, 4, and 9 exhibit
differential spatio-temporal expression patterns according to menstrual cycle changes, where
there is a general increase in expression of all four TLRs around menstruation and a decrease in
expression around ovulation (Hirata, Osuga et al. 2007). Estrogen suppresses TLR3-dependent
proinflammatory and anti-viral cytokine and chemokine production in endometrial epithelial cell
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lines (Schaefer, Fahey et al. 2005; Lesmeister, Bothwell et al. 2006). Female peripheral blood
lymphocytes (PBLs) produce significantly higher IFN-α levels in response to TLR7 stimulation
compared with male PBLs (Berghofer, Frommer et al. 2006).

Estrogen also modulates FcγR expression. Pregnancy levels of estrogen enhance clearance of
IgG-sensitized erythrocytes by increasing splenic FcγR1 and FcγR2 expression in guinea pigs
(Friedman, Netti et al. 1985; Gomez, Ruiz et al. 2001) while androgens, including testosterone,
have the opposite effect (Gomez, Ruiz et al. 2000). In human PBLs and monocytic cell lines,
removal of estrogen results in increased FcγR transcripts as well as increased TNF-α, IL-1β and
IL-6 production upon receptor cross-linking (Kramer, Kramer et al. 2004; Kramer, Winger et al.
2007).

Mycobacterium tuberculosis, the causative agent of tuberculosis, is an intracellular pathogen
capable of surviving and persisting within host mononuclear cells, such as macrophages
(Quesniaux, Fremond et al. 2004). The mediators that are essential for control of M. tuberculosis
infection are secreted by macrophages and activated lymphocytes and include IFN-γ, IL-12,
TNF, lymphotoxins, CD40 and nitric oxide (Garcia, Guler et al. 2000; Jacobs, Marino et al.
2000; Holscher, Atkinson et al. 2001; Lazarevic, Myers et al. 2003). One way that mycobacteria
have evolved to resist clearance by macrophages is by inhibition of phogosome-lysosome fusion.
Another way is by neutralization of some of these mediators (TNF and IFN-γ), inhibition of
iNOS and T cell depletion (Flynn and Chan 2003). Therefore, continuous activation of
macrophages in concert with activated T cells is necessary to control infection.

80

When studying resistance against M. tuberculosis infection and pathogenesis, much of the focus
has been on the proteins actively secreted from the bacteria during their growth in culture. These
secreted proteins, termed culture filtrate proteins (CFP) are released into the medium of
mycobacterial cultures and are the primary targets for the immune response in mice and humans
with active tuberculosis. Furthermore, they are the major proteins involved in M. tuberculosis
pathogenesis. CFP have been extensively characterized and employed in experimental vaccine
studies using mice. They have been studied as single proteins, or in pools of several proteins. To
date, there have not been any studies that have specifically addressed the influence of sex
hormones on M. tuberculosis vaccine responses. Because CFP is well-studied and safe to
administer to animals, we used M. tuberculosis CFP as a model vaccine to a ssess how estrogen
modulates the immune response to immunization. We have previously shown that estrogen
enhances humoral immune responses to vaccination. The enhancement mechanism is not fully
understood. We carried out this study to determine whether estrogen influences macrophage
function, which is necessary for response to pathogens and for activation of downstream adaptive
responses. To activate the immune system, female mice that were intact, ovariectomized
(OVEX), or ovariectomized and received estrogen replacement (OVEX-E2) were subjected to
immunization with M. tuberculosis CFP. We then measured TLR2 as well as FcγRI, FcγRIIB
and FcγRIIIA gene expression in primary splenic and thioglycollate-elicited macrophages to
determine if these genes are hormonally regulated in the immune response to vaccination. In
addition, TLR2, FcγRI, FcγRIIB and FcγRIIIA gene expression was measured in a group of nonimmunized male mice.
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TLR2 and FcγR are critical for proper activation of the immune response. Indeed, vaccination
relies on such functions in order to effectively trigger immunity during secondary infection.
Therefore, hormonal modulation of these receptors could be an important pathway which
directly influences not only autoimmune disease states in females, but also by which immune
responses to vaccination can be manipulated.

MATERIALS & METHODS
Animals
Eight week-old female Balb/c mice (Charles River Laboratories, Inc., Wilmington, MA) were
divided into 3 experimental groups. The first group, designated OVEX-E2 group, was
ovariectomized and subjected to estrogen replacement. The second group, designated OVEX
group, received no estrogen replacement (Table 4.1). The third group remained intact. All
animals were housed and subjected to experimental procedures in accordance to protocols
approved by the appropriate institutional review committee.

Ovariectomy, E2 replacement, and uterotrophic responses
Mice were anesthetized with 5% isoflurane gas in 100% oxygen, and their ovaries, oviducts and
tips of the uterine horns were bilaterally removed via two dorsal incisions. Immediately
following surgery, mice in the OVEX-E2 group started E2 replacement. E2 was administered in
the drinking water. E2-treated water was prepared as previously described by diluting stock
solutions of E2 (Sigma- Aldrich Corp., St. Louis, MO) in 100% ethanol to solubilize (LevinAllerhand, Sokol et al. 2003). Solubilized estrogen was added to drinking water to produce a
final concentration of 1000 nM, as previously described
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Table 4.1. Experimental design for E2-CFP study.
Mice were divided into 3 groups, where the first group was ovariectomized (OVEX), the second
group was ovarietomized and was given 1000 nM 17β-estradiol (E2) replacement in the drinking
water (OVEX-E2), and the third group underwent sham ovariectomy (intact). Mice were then
vaccinated with M. tuberculosis CFP. Within each of these groups, one third of mice were
vaccinated with 10 ug CFP (CFP-10), one third received 50 ug CFP (CFP-50) and the final third
received saline (unvaccinated).

Hormone group

Vaccine group

Group Designation

OVEX

10 ug CFP

OVEX, CFP-10

11

50 ug CFP

OVEX, CFP-50

11

Unvaccinated

OVEX, UNVAX

10

10 ug CFP

OVEX-E2, CFP-10

11

50 ug CFP

OVEX-E2, CFP-50

11

Unvaccinated

OVEX-E2, UNVAX

10

10 ug CFP

Intact, CFP-10

11

50 ug CFP

Intact, CFP-50

11

Unvaccinated

Intact, UNVAX

10

Unvaccinated

Male

6

OVEX-E2

Sham OVEX

Untreated males

No. of mice
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(Levin-Allerhand, Sokol et al. 2003; Fernandez and Frick 2004). The final concentration of
ethanol was 0.1%. No adverse effects of this concentration of ethanol or estrogen were reported
(Levin-Allerhand, Sokol et al. 2003). The selected concentration of E2 results in an ingested
dose of approximately 50-70 kg/ug per day, corresponding to about 15 pg/ml (Stone, Rozovsky
et al. 1998; Levin-Allerhand, Sokol et al. 2003). Estrogen levels during the estrus cycle in mice
typically range from 10-40 pg/ml (Nelson, Karelus et al. 1995). A 1000 nM dose in the drinking
water was previously shown to result in uterine weights that were significantly higher than
control mice, yet not significantly different from those of mice given either 1500 nM or 2500 nM
doses, implying a uterotrophic response that plateaus with increasing E2 doses (Levin-Allerhand,
Sokol et al. 2003). To test for uterotrophic responses, uteri were removed and weighed at
termination.

Immunization
Mice were immunized with a primary (day 0), secondary (day 21) and tertiary (day 49) dose of
M. tuberculosis CFP (Provided by J. T. Belisle, Colorado State University, Fort Collins, CO,
under the National Institutes of Health, National Institute of Allergy and Infectious Diseases
Contract NO1-AI-75320, titled Tuberculosis Research Materials and Vaccine Testing) (Figure
4.1). Mice received subcutaneous injections of either 10 ug or 50 ug of CFP, mixed with Imject
Alum (Pierce, Rockford, IL) at a 2 to 1 ratio of CFP to Alum. Formulations were made in a final
volume of 200ul, yielding a final dose of either 50 ug/ml or 250 ug/ml.

84

Isolation of splenic and thioglycollate-elicited macrophages
Splenic macrophages were isolated by passing cells through a 70um nylon mesh (BD-Falcon,
Bedford, MA), and blood cells were removed using Red Blood Cell Lysis Buffer (Sigma Aldrich
Corp., St. Louis, MO). Cells were adjusted to 3x106 cells/ml in complete medium (DMEM
containing 100 U/ml penicillin, 100 ug/ml streptomycin, 1 mM glutamine and 5% FBS) in 6-well
plates in a final volume of 2.5 ml/well for 60 min at 37C with 5% CO2. Wells were rinsed with
media to remove non-adherent cells. Remaining cells were used for RNA extraction. To induce
activated peritoneal macrophages, 1 ml of 3% thioglycollate was injected i.p. into mice. Five
days later, peritoneal exudates cells were collected in 10 ml of cold PBS. Cells were washed and
incubated at 1x106 cells/ml in 2.5ml complete medium for 60 min and non-adherent cells were
removed.

Macrophage stimulation
Thioglycollate-elicited and splenic macrophages (1x10^6 cells/ml) were stimulated in 12-well
plates in a final volume of 2.5 ml/well with 1ug/ml LAM (CSU), 5ug/ml LAM, 10 ug/ml LAM,
10 ug/ml peptidoglycan (PGN, Sigma), 100 ug/ml PGN or media alone. Cultures were incubated
for 4 hr and 48 hr at 37C with 5% CO2. Media was then removed and RNA was extracted from
cells and used to determine TLR2 and FcγR expression by real-time PCR.

TLR2 expression detected by real-time PCR
Total RNA was isolated using Qiagen RNeasy Mini Kit (Qiagen, Valencia, CA) according to
manufacturer’s instructions. RNA samples were quantified and used for cDNA synthesis using
First Strand cDNA Synthesis Kit for RT-PCR (AMV) (Roche Diagnostics Corp., Indianapolis,
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OVX/ E2
treatment

-56

-49

CFP Immunization
1st Dose

2nd Dose

3rd Dose

0

21

49

Terminal
bleed/
sacrifice

63

~ 3.5 months

Figure 4.1. E2-CFP Study: Hormone treatment and vaccination schedule.
Mice were ovariectomized and mice designated to receive E2 replacement were immediately
given E2 (1000 nM) orally in their drinking water. Mice were vaccinated on Day 0 with M.
tuberculosis CFP, and then received subsequent booster doses on Days 21 and 49. All mice were
sacrificed on day 63 for uterine weight measurements as well as macrophage isolation from the
peritoneal cavity and the spleen. The large arrows indicate dates of vaccine administration. The
small arrows indicate days of blood collection for determination of CFP-specific antibody
responses.

86

IN) using approximately 1ug of total RNA. Real-time PCR was performed using TaqMan Gene
Expression Assays pre-developed primers and probes for TLR2 at a 1 X concentration, 10ul of
cDNA and 1 X TaqMan Gene Expression Master Mix (all supplied by Applied Biosystems,
Foster City, CA). Relative quantification was determined by normalizing TLR2 expression to
endogenous β-actin expression. ΔΔCt values were calculated by calibrating average ΔCt values
of the OVEX-E2 and OVEX mice to those of the intact mice.

Detection of CFP-specific antibody responses
Anti-CFP antibody responses were assessed by ELISA. Micro-titer wells were coated with CFP
at 4 ug/ml diluted in coating buffer (KPL, Inc., Gaithersburg, MD). To block nonspecific binding
sites, wells were incubated for 30 min at 37ºC with PBS containing 5% fetal calf serum (FCSPBS) (Atlanta Biologicals, Lawrenceville, GA). Two-fold serial dilutions were performed on
serum samples which were then added to triplicate wells and incubated overnight at 4º C. After
washing with PBS containing 0.05% Tween-20, wells were incubated with HRP-labeled goat
anti-mouse IgG (γ) (KPL, Gaithersberg, MD) for 1 hr and 15 min at 37º C. Wells were washed
and then incubated with ABTS/ H2O2 (KPL) substrate for 10 min at room temperature, followed
by addition of stop solution (KPL). Optical density (OD) values were assessed at 405 nm using a
PowerWave HT plate reader (BioTek Instruments, Inc., Winooski, VT).

Statistical analysis
The SPSS program (SPSS Inc, Chicago, Illinois) version 12 was used for statistical analysis.
Analysis among multi-group data was carried out using ANOVA, followed by Turkey's
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significant difference test, or Tamhane's T2 test when the test of homogeneity of variances
(Levene Statistic) indicated that the variance between the groups was not equal. Differences
among groups were considered significant if p < 0.05.

RESULTS
Uterotrophic responses
Mice were sacrificed after being subjected to approximately 3.5 months of ovariectomy with or
without E2 replacement. At termination, uteri from each mouse were collected and weighed in
order to test for uterotrophic responses to E2 delivery. This bioassay was chosen because of its
high sensitivity to low amounts of E2 treatment (Mobbs, Cheyney et al. 1985). The mean uterine
weights were compared between the groups. As expected, OVEX-E2 mice had uterine weights
significantly higher than the OVEX and intact mice (p < 0.001). The uterine weights of OVEX
mice were significantly lower than those of the intact mice (p < 0.001) (Figure 4.2). This
confirms the desired effect of a supra-physiological level of E2 as a result of our method of
delivering 1000 nM of E2 in the drinking water of OVEX mice.

Estrogen manipulation modulates TLR2 and FcγIIIA mRNA expression in macrophages
isolated from non-vaccinated mice
To determine the effect of estrogen manipulation alone on macrophage gene expression, we
measured and compared TLR2 and FcγR mRNA in unvaccinated OVEX-E2, OVEX and intact
mice. Our results show that E2-replacement correlated with a reduction in TLR2 mRNA
expression. Compared with intact mice, TLR2 expression in OVEX-E2 mice was 42% reduced
in peritoneal macrophages and 60% reduced in splenic macrophages (Figure 4.3). On the other
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Weight (g)

0.22
0.20
0.18
0.16
0.14
0.12
0.10
0.08
0.06
0.04
0.02
0.00

*
**
*

OVEX

INTACT

OVEX-E2

TREATMENT

UTERINE WEIGHT (mg)

OVEX

0.069 ± 0.020 *

INTACT

0.108 ± 0.026 **

OVEX-E2

0.176 ± 0.040

Figure 4.2. Uterotrophic responses to hormone treatment.
Approximately 3.5 months after hormone manipulation, female mice were sacrificed and uteri
were removed and weighed to compare uterotrophic responses between groups. *p < 0.001
compared to intact and OVEX-E2, ** p < 0.001 compared to OVEX and OVEX-E2.
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3.0
2.5

OVEX-E2
OVEX
INTACT

Fold Δ

2.0
1.5
1.0
0.5
0.0
TLR2

FcgRI

FcgRIIB

Peritoneal

FcgRIIA

TLR2

FcgRIIA

Spleen

Figure 4.3. The effect of estrogen manipulation on macrophage gene expression.

Splenic and thioglycollate-elicited macrophages from OVEX-E2, OVEX and intact mice were
isolated and total RNA was extracted and used for cDNA generation and real time PCR to
measure leavels of TLR2, FcγRI, FcγRIIB and FcγRIIIA mRNA expression. Data are expressed
as fold difference (2 -ΔΔCt) of OVEX-E2 and OVEX mice compared with intact mice (set to 1).
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hand, OVEX mice showed a 17% increase in TLR2 mRNA expression compared to intact mice
in peritoneal macrophages. In splenic macrophages, a lesser increase in TLR2 mRNA expression
of only 6% in the OVEX mice was seen. OVEX mice expressed 139% more FcγRIIIA mRNA in
peritoneal macrophages compared to intact mice. These patterns of E2-induced down-regulation
were not observed when we measured FcγRI and FcγRIIB.

M. tuberculosis CFP-specific antibody responses
To test the effect of hormone treatment on specific response to vaccination, we measured serum
levels of anti-CFP IgG in OVEX-E2, OVEX and intact mice. Mice were vaccinated with a total
of three doses of 10 ug or 50 ug CFP, designated CFP-10 and CFP-50, respectively. Blood was
collected according to the schedule indicated above (Figure 4.1) and serum was diluted and used
for determination of specific antibody responses. After the third dose, OVEX mice in the CFP-10
group had significantly lower CFP-specific IgG levels compared to OVEX-E2 mice and reduced,
although not significantly, lower anti-CFP IgG levels compared with the intact mice (Figure 4.4
A). These differences were more dramatic in the CFP-10 vaccination group than the CFP-50
group. Overall, CFP-50 mice showed higher responses than did the CFP-50 mice, likely due to
the higher dose administered. These mice showed differences at higher serum dilutions of 1:800,
where OVEX mice had reduced anti-CFP antibody responses compared to the OVEX-E2 and
intact mice (p < 0.05 compared to intact mice) (Figure 4.4 B).
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*
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1: 50
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Serum Dilution

Figure 4.4. CFP-specific antibody responses.

Mice were vaccinated with a total of three doses of either A, 10 ug or B, 50 ug M. tuberculosis
CFP. Blood was collected two weeks after the third dose was administered and serum was used
for determination of anti-CFP IgG (γ) levels. Data expressed as OD values of the average of 10
or 11 mice per group ± SEM. * p < 0.05, ** p < 0.01.
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Macrophage TLR2 expression is enhanced in OVEX mice and reduced in E2-treated mice
following vaccination
It is well-known that LAM from M. tuberculosis, also present in CFP, activates macrophages
through TLR2. Our data shows that in normal intact female mice, vaccination with M.
tuberculosis CFP results in up-regulation of TLR2 expression in thioglycollate-elicited
macrophages. In both CFP-10 and CFP-50-vaccinated OVEX mice, this increase was more
pronounced after vaccination when compared with the increase seen in the intact mice (Figure
4.5). In OVEX-E2 mice, vaccination caused reduced TLR2 mRNA expression compared to the
response seen in the OVEX and intact mice. Interestingly, in CFP-10-vaccinated OVEX-E2
mice, TLR2 expression was down-regulated when compared with the unvaccinated OVEX-E2
mice. These data suggest that in the absence of E2, TLR2 mRNA expression in response to CFP
is enhanced, whereas high levels of E2 cause a reduction of TLR2 mRNA expression in response
to CFP. Such a pattern was most pronounced in the in CFP-10 vaccinated mice, thus indicating a
possible dose-response effect. Similar vaccine-induced changes in TLR2 mRNA expression were
not seen with the FcγR mRNA expression in the same mice (data not shown).

Vaccination and/or estrogen manipulation differentially effect TLR2 and FcγR gene
expression in mice
Thioglycollate-elicited macrophages were isolated from OVEX-E2, OVEX and intact mice that
were either unvaccinated or vaccinated with CFP-10 or CFP-50. To determine the effects of
these treatments, alone or in combination, on macrophage gene expression, RNA from these cells
was used for cDNA synthesis and real time PCR determination of TLR2 and FcγR mRNA
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Figure 4.5. The effect of vaccination on TLR2 gene expression.
Real time PCR was used to determine TLR2 mRNA expression in thioglycollate-elicited
peritoneal macrophages from unvaccinated mice and mice vaccinated with 10 ug (CFP-10) or 50
ug (CFP-50) M. tuberculosis CFP. Data are expressed as fold difference (2

-ΔΔCt

) of vaccinated

mice compared with unvaccinated mice (set to 1).
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Figure 4.6. The effect of vaccination and/or estrogen on TLR2 and FcγR gene expression
(next page).

Thioglycollate-elicited macrophages were isolated from mice and RNA was extracted and cDNA
used for real time PCR determination of levels of A, TLR2, B, FcγRI, C, FcγRIIB and D,
FcγRIIIA mRNA expression. Bars represent the average values of individual mice per group (n=
10 or 11). Bars depict mRNA levels of the indicated gene for each group in response to the
indicated treatment. Data are expressed as fold difference (2

-ΔΔCt

) of treated mice (filled bars)

compared to those of the untreated intact mice (empty bars, set to 1) for each gene indicated.

95

INTACT
OVEX
OVEX-E2
INTACT
OVEX

OVEX

FcγRIIIA

3.0

CFP50

CFP50

2.0

CFP10

UNVAX

CFP50

CFP10

UNVAX

CFP50

CFP10

Fold Δ

FcγRI

CFP10

UNVAX

1.5

CFP50

0.0
INTACT

CFP10

0.5
UNVAX

CFP50

A

UNVAX

C

CFP50

OVEX-E2

CFP10

2.0
CFP10

Unvax

CFP50

CFP10

Unvax

CFP50

CFP10

Unvax

Fold Δ
4.5
4.0
3.5
3.0
2.5
2.0
1.5
1.0
0.5
0.0

UNVAX

1.0
Fold Δ

FcγRIIB

CFP50

OVEX

CFP10

UNVAX

CFP50

INTACT

CFP10

UNVAX

CFP50

CFP10

UNVAX

Fold Δ

TLR2

B

1.5

1.0

0.5

0.0

OVEX-E2

D

2.5

2.0

1.5

1.0

0.5

0.0

OVEX-E2

Figure 4.6.
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expression. Figure 4.6 shows the expression patterns of each receptor according to the indicated
treatment. These results indicate that gene expression patterns may vary with vaccination and/or
estrogen manipulation (OVEX or OVEX-E2) (Figure 4.6 A, B). The most dramatic difference in
gene expression related to estrogen manipulation but not vaccination was seen with FcγRIIIA
(Figure 4.6 D). No difference in gene expression caused by such treatments was seen with
FcγRIIB (Figure 4.6 C). Comparison of treated mice with untreated mice (unvax, intact mice)
shows that macrophage gene expression levels are responsive and differentially affected
depending on the receptor and type of treatment.

To determine the effect of estrogen on TLR2 and FcγR expression, within independent vaccine
treatment, the data generated from the same mice was reanalyzed to compare gene expression
levels of OVEX-E2 and OVEX mice with those of intact mice within each vaccine group. Our
data show that TLR2 mRNA expression is significantly reduced in OVEX-E2 mice, irrespective
of vaccination (Figure 4.7 A). Furthermore, there was a slight up-regulation of TLR2 mRNA
expression in OVEX mice compared with intact mice. FcγR mRNA expression patterns varied
greatly between the three types. FcγRI mRNA expression was significantly enhanced in OVEX
and reduced in OVEX-E2 mice compared with intact mice in the CFP-10 vaccine group, whereas
there were no differences in the CFP-50 vaccine group (Figure 4.7 B). FcγRIIIA mRNA
expression was up-regulated in OVEX mice compared with intact mice irrespective of
vaccination. However OVEX-E2 mice showed reduced FcγRIIIA mRNA levels only in the CFP10 vaccine group (Figure 4.7 D).
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Figure 4.7. The effect of estrogen on TLR2 and FcγR gene expression (next page).

Thioglycollate-elicited peritoneal macrophages were isolated from mice, RNA was extracted and
cDNA was used for real time PCR determination of levels of A, TLR2, B, FcγRI, C, FcγRIIB
and D, FcγRIIIA mRNA expression. Bars represent the average values of individual mice per
group (n= 10 or 11). Bars depict mRNA levels of the indicated gene for each group in response
to the indicated treatment. Data are expressed as fold differences (2 -ΔΔCt) of OVEX-E2, OVEX
mice compared to intact mice (set to 1 for each gene indicated. * p < 0.05, ** p < 0.01.
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Figure 4.7
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In vitro stimulation of macrophages with TLR2 ligands differentially up-regulates
macrophage TLR2 mRNA expression in vaccinated and/or estrogen-manipulated mice
Our data so far show similar estrogen-modulated patterns of TLR2 and FcγR mRNA expression,
where E2 generally reduces and OVEX enhances mRNA expression, with the exception of
FcγRIIB, where no changes are seen. Common TLR2 ligands include gram-positive bacterial
products such as peptidoglycoan (PGN). Lipoarabinomannan (LAM) is a mycobacterial cell wall
component that is also known to activate and unpregulate TLR2 (Tapping and Tobias 2003;
Quesniaux, Nicolle et al. 2004) and is present in mycobacterial culture filtrate preparations. Mice
that are vaccinated with CFP have an advantage when encountering mycobacterial proteins
because they have been primed to respond to secondary encounter. Therefore, we next
determined whether estrogen manipulation affects macrophage responsiveness to in vitro
stimulation with known TLR2 ligands in CFP-vaccinated and in unvaccinated mice.

Thioglycollate-elicited peritoneal macrophages were cultured for 48 hr in the presence of TLR2
ligands LAM (1 ug/ml and 10 ug/ml) and PGN (100 ug/ml). Total RNA was extracted and used
for cDNA generation followed by real time PCR for detection of TLR2 transcripts. In
unvaccinated mice, stimulation with PGN resulted in increased expression compared to the
unstimulated controls, and these levels varied with respect to estrogen manipulation, where
OVEX mice had up-regulated, and OVEX-E2 had down- regulated TLR2 expression compared
with the intact mice (Figure 4.8 A). Very little differences in TLR2 mRNA expression were seen
in response to stimulation with LAM when compared with the unstimulated control. This was
not surprising since these mice were unvaccinated and therefore were not primed with CFP to
respond as in a secondary encounter to LAM.
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When mice were vaccinated with CFP, macrophage stimulation with LAM resulted in increased
TLR2 expression in a dose-dependent manner. Stimulation with PGN in these groups served as a
positive control for TLR2 expression based on the results from the unvaccinated group. In the
CFP-10 vaccine group, there was a significant reduction in TLR2 mRNA expression in the
OVEX-E2 mice compared to both the OVEX and intact, indicating a strong down-regulatory
effect of estrogen (Figure 4.8 B). In the CFP-50 group, this reduction was apparent yet more
subtle (Figure 4.8 C). Overall, TLR2 mRNA expression in stimulated macrophages was downregulated in OVEX-E2 mice when compared with intact mice. OVEX mice showed equal or
slightly up-regulated expression when compared to intact mice (Figure 4.8 B and C). Though
both groups responded in a similar pattern to stimulation, mice vaccinated with CFP-10 showed
higher TLR2 levels as compared with CFP-50. Furthermore, differences between OVEX-E2
mice and OVEX/intact mice were more pronounced in the CFP-10 group, indicating a CFPvaccine dose response. This pattern of TLR2 mRNA expression was identical in splenic
macrophages (data not shown).

The data discussed above focuses on TLR2 expression patterns of stimulated cells compared
with un-stimulated control cells and show how treatment (vaccination and/or estrogen
manipulation) affects TLR2 expression. Additional analysis was performed to compare TLR2
mRNA expression in the three hormone groups for each independent in vitro stimulation
conditions. These data show consistent up-regulation of TLR2 mRNA expression in OVEX
mice compared with intact mice, irrespective of vaccine dose and in vitro stimulation conditions
(Figure 4.9). TLR2 mRNA expression was up-regulated from 36% up to 200% depending on the
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Figure 4.8. The effects of estrogen on TLR2 gene expression in response to in vitro
stimulation with TLR2 ligands (next page).

Thioglycollate-elicited peritoneal macrophages from A, unvaccinated mice or mice vaccinated
with B, 10 ug CFP (CFP-50) or C, 50 ug CFP (CFP-10) were pooled according to group (n = 10
or 11 mice per group) and cultured for 48 hrs in the presence of 1 ug/ml and 10 ug/ml
mycobacterial lipoarabinomannan (LAM) and 100 ug/ml peptidoglycan (PGN). RNA extracted
from these cells was used for real time PCR determination of levels of TLR2 transcripts. Bars
depict TLR2 mRNA levels of each group in response to the indicated stimulator. Data are
expressed as fold difference (2-ΔΔCt) of the stimulated cells (filled bars) compared to those of the
unstimulated controls (empty bars, set to 1) for each hormone and vaccine treatment.
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Figure 4.9. OVEX up-regulates TLR2 mRNA expression after stimulation with TLR2 ligands.
Thioglycollate-elicited peritoneal macrophages from mice vaccinated with A, 10 ug CFP (CFP-50) or B, 50 ug CFP (CFP-10) were
pooled (n= 11) and stimulated for 48 hrs with LAM or PGN and RNA was used for real time PCR detection of TLR2 expression. Data
expressed as fold difference (2
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) of OVEX-E2 and OVEX mice (filled bars) compared to intact mice (empty bars, set to 1).

Percent increase of TLR2 expression in the OVEX compared with the intact mice is indicated for each group.
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type of stimulation and vaccine dose group. These data further indicate that in the absence of
estrogen, CFP-primed macrophages express increased TLR2 transcripts in response to LAM and
PGN compared to OVEX-E2 and intact control mice. TLR2 mRNA expression did not differ
between OVEX-E2 and intact mice in response to in vitro stimulation with LAM or PGN.

Macrophage TLR2 and FcγR mRNA expression differs between male and female mice
Based on the observed differences between OVEX-E2, OVEX and intact mice, it is thus far clear
that absence of estrogen results in up-regulated expression of TLR2, FcγRI and FcγRIIIA,
whereas in presence of high levels of estrogen (OVEX-E2 mice), gene expression levels are
down-regulated. Since estrogen levels differ greatly between males and females, we next
compared baseline TLR2 and FcγR mRNA expression of intact female mice with those of male
mice. For this comparison, we used thioglycollate-elicited peritoneal macrophages (all receptors)
as well as splenic macrophages (TLR2 and FcγRIIIA only) to determine if expression differs
within different tissues and compartments. Macrophages were obtained from individual female
and male mice and total RNA was extracted and used for cDNA generation and realtime PCR to
detect levels of TLR2 mRNA expression. In splenic macrophages, males expressed significantly
higher levels of TLR2 and FcγRIIIA mRNA compared to females (p < 0.01) (Figure 4.10). In
thioglycollate-elicited peritoneal macrophages, levels of TLR2, FcγRI and FcγRIIIA were
significantly higher in the male mice compared with the female mice (p < 0.05 for TLR2 and p <
0.01 for FcγRI and FcγRIIIA). No gender-related differences in FcγRIIB mRNA expression were
observed.
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Figure 4.10. Sex differences in TLR2 and FcγR gene expression.
Thioglycollate-elicited peritoneal macrophages and splenic macrophages were isolated from
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time PCR determination of transcript levels of TLR2, FcγRI, FcγRIIB, FcγRIIIA. Bars represent
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To compare differences in expression under all hormone conditions TLR2 and FcγR, data were
re-analyzed to include the unvaccinated female OVEX-E2, OVEX and intact mice along with
male mice. In peritoneal macrophages, TLR2 mRNA expression in male mice was up regulated
compared to OVEX-E2, OVEX and intact female mice, although statistical significance was only
observed when compared with the OVEX-E2 mice (p < 0.05). In splenic macrophages, male
mice expressed significantly higher levels of TLR2 mRNA compared with all groups of females
(p < 0.01) (Figure 4.11 A). FcγR mRNA levels were determined in peritoneal macrophages.
FcγRI and FcγRIIIA mRNA expression levels were higher in males compared with females (p <
0.01) (Figure 4.11 B). No gender differences were observed in FcγRIIB mRNA expression.

DISCUSSION

To study the effects of estrogen on macrophage gene expression, female Balb/c mice were
ovariectomized to remove endogenously-produced E2. A group of these mice was then given E2
replacement in supra-physiological levels. E2 was diluted in the drinking water of designated
mice. This administration method is a common and safer alternative to other methods of
hormone delivery based on osmotic pumps, silastic implants or injections. This method resulted
in significantly different uterotrophic responses when compared to OVEX and intact mice,
confirming sufficient E2 delivery.

In studying the effects of estrogen on macrophage function, we focused on TLR2 and FcγR gene
expression, as these receptors are involved in innate and adaptive immune responses,
respectively. Therefore, estrogen-induced changes in receptor expression are expected to result
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in significant alterations in immune function. Our data suggest a general up-regulation of
macrophage gene expression in the absence of estrogen. OVEX mice expressed higher levels,
whereas OVEX-E2 mice expressed lower levels, of TLR2, FcγRI and FcγIIIA. These results
indicate that E2 down-regulates expression of these genes, as even intact mice, which produce
physiological levels E2 showed slightly lower expression than did OVEX mice. When these
groups were compared with male mice of identical age and subjected to the same housing and
diet conditions, male mice expressed significantly higher levels of mRNA of these genes.
Although males do endogenously produce estrogen through conversion of testosterone and other
biosynthetic pathways, it is implied that this effect involves a more complex regulation of
macrophage gene expression by sex hormones, as even differences between males and OVEX
mice were drastically different. FcγRIIB consistently showed no change in mRNA expression
between the groups, nor between males and females.

FcγRI and FcγRIIIA are both expressed on myeloid cells (monocytes and macrophages) and both
require the presence of associated subunits (γ or ζ) to be expressed on the cell surface and to
transduce cell-activating signals (Nimmerjahn and Ravetch 2006; Kuby 2007). These two
receptors are considered activating FcγR because they induce ADCC, endocytosis of immune
complexes followed by antigen presentation, phagocytosis and release of cytokines or proinflammatory mediators. FcγRIIB, on the other hand, transduces inhibitory signals that downregulate immune functions triggered by activating receptors, and is therefore considered an
inhibitory FcγR. Differential patterns of FcγR expression induced by estrogen, therefore, is not
surprising given the distinct functions of these receptors.
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FcγRIIB is the only classic Fc receptor present on B cells where it regulates activating signals
resulting from immune complex binding to the B cell receptor (BCR) (Phillips and Parker 1983).
Normally, B cell signaling results in proliferation, class-switching and maturation into antibodysecreting plasma cells. FcγRIIB-deficient mice who display elevated levels of Ig. FcγRIIB also
plays a role in peripheral tolerance, where deficient mice spontaneously develop lupus-like
disease with high autoantibody production (Bolland and Ravetch 2000). Additionally,
polymorphisms in the FcgRIIB gene leading to decreased transcription and surface expression on
B cells of lupus patients have been identified (Blank, Stefanescu et al. 2005). Interestingly, when
studied in equivalent animal models, the monocytic compartment still expressed FcγRIIB, while
it was absent from peripheral B cells (Bolland and Ravetch 2000). Therefore, the present study,
where estrogen treatment up-regulated specific antibody responses to vaccination, is consistent
with the finding that although the activating Fc receptors were downregulated by estrogen, the
inhibiting receptor which acts mostly on B cells, was not similarly affected by estrogen.

It is important to consider that hormonally-influenced immune modulation often times may not
be apparent until activation of the immune system occurs, such as of immune cells during a
vaccine response or during infection. During immune activation, the response to estrogen may be
different than in an absence of activation. To test this hypothesis, we used a vaccine model
consisting of M. tuberculosis CFP administered to mice in one of two dose concentrations (CFP10 and CFP-50). In order to determine macrophage gene expression changes in response to
antigenic stimulation under such hormonal conditions, OVEX-E2, OVEX and intact mice were
vaccinated with M. tuberculosis CFP to induce immune activation. In the unvaccinated groups,
we observed significantly increased TLR2 mRNA expression in peritoneal macrophages from
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OVEX mice compared with intact and OVEX-E2 female mice, with the fold difference in
expression most pronounced in OVEX mice. On the other hand, in the vaccinated groups,
OVEX-E2 mice, there was a vaccine-induced decrease in TLR2 mRNA expression when
compared with unvaccinated mice. These results support the hypothesis of an estrogen-related
difference in macrophage activation and gene regulation in response to vaccination. Indeed,
TLR2 gene expression post-vaccination was significantly higher in OVEX mice than prior to
vaccination and was also significantly higher than both the intact and OVEX-E2 mice.

We have previously shown that estrogen enhances vaccine-specific antibody responses in mice
(Chapter 3). We tested anti-CFP antibody responses to confirm the presence of a specific
immune response, and therefore, immune activation. Patterns of antibody responses were
negatively correlated with patterns observed for TLR2 and FcγR expression. CFP-vaccinated
OVEX mice showed reductions anti-CFP IgG levels when compared with OVEX-E2 and intact
mice. Unlike macrophage TLR2 and FcγR mRNA expression, we did not observe a difference in
antibody responses between OVEX-E2 and intact mice, indicating that in the absence of
estrogen, the immune response is more sensitive to humoral CFP vaccine responses than in
presence of supra-physiological estrogen levels. This reduced antibody response negatively
correlates with the observed increases in TLR2 and FcγRI and FcgIIIA gene expression in
OVEX mice compared to the intact mice. CFP-10 and CFP-50-vaccinated OVEX-E2 mice
showed decreased TLR2 and I and FcγRIIIA expression, whereas OVEX mice showed slight upregulation of expression. Therefore, in an activated immune system, in this case during a vaccine
response, estrogen manipulation may not significantly alter the observed patterns of estrogeninduced modulation of macrophage gene expression, as seen in the unvaccinated mice.
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M. tuberculosis is a gram-positive bacillus that, when sequestered, releases mycobacterial
products (glycolipids, lipoproteins, secreted factors, etc.) that contribute to continued
macrophage activation through TLR and MyD88-mediated signaling (Quesniaux, Fremond et al.
2004). An identified vilrulence factor of M. tuberculosis is the cell wall component
lipoarabinomannan (LAM). Present in CFP, this has been shown to modulate a variety of
immune activities including inhibition of phagosome maturation, apoptosis and IFN-γ signaling
in macrophages and IL-12 secretion from decdritic cells (DC) (Pathak, Basu et al. 2007). It has
been shown that that mycobacterial glycolipids such as LAM and its biosynthetic precursor
lipomannan (LM) activate cells through TLR2 signaling (Rock, Hardiman et al. 1998).
Therefore, it was not surprising that vaccination of mice with CFP up-regulated TLR2. The
observed differences in TLR2 expression between the OVEX-E2 and OVEX mice compared to
the intact mice implies that estrogen modulates CFP-induced TLR2 mRNA expression. The
general pattern of E2-mediated down-regulation of TLR2 and FcγRIII appeared to be more
pronounced in mice vaccinated with low-dose CFP, as a high-dose CFP appears to mask this
effect.

Macrophages are critical components of innate immunity. Variability in TLR expression patterns
may influence initial pathogen recognition and the subsequent response elicited. Indeed, results
from our stimulation experiments show that splenic and thioglycollate-elicited peritoneal
macrophages isolated from OVEX-E2, OVEX and intact mice respond differently to in vitro
stimulation with TLR2 ligands, LAM and PGN. Although there are variations depending on the
cell type and the dose of stimulator used, the general trend supports that OVEX mice appear to
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have up-regulated levels of TLR2, and OVEX-E2 mice showed down-regulated levels of TLR2.
In general, the differences seen between the groups were greater in CFP-10-vaccinated compared
with those vaccinated with CFP-50-vaccinated mice. Splenic macrophages from CFP-50vaccinated OVEX-E2, OVEX and intact mice did not show differences in TLR2 expression in
response to stimulation. Comparison of the three hormone groups at each stimulator highlights a
pattern in which OVEX mice appear to up-regulate TLR2 mRNA compared to OVEX-E2 and
intact mice, although OVEX-E2 and intact mice do appear to differ in this respect.

Our results are consistent with studies which have shown that FcγRIIIA transcript increases in
the human monocytic cell line THP-1 and primary macrophages in the absence of E2 (Kramer,
Kramer et al. 2004). The finding that FcγRIIIA cross-linking stimulates production of TNF-α,
IL-1β and IL-6 in the absence of E2 indicates that the modulation of proinflammatory cytokine
release from activated monocytes/macrophages occurs in part through modulation of FcγRIIA
gene expression. Other studies using a guinea pig model show results contrary to ours. In these
studies, estrogens enhanced, and androgens impaired, clearance of IgG-sensitized erythrocytes
by increasing FcγRIIIA expression on splenic macrophages (Gomez, Ruiz et al. 2000; Gomez,
Ruiz et al. 2001). While guinea pigs express two forms of this receptor, known as FcγΡ1 and
FcγR2, they have no form of FcγRIIIA as do humans and mice. Therefore, expression patterns
may vary with the type of receptor and thus these two species cannot be compared.

Besides differences in gene expression with respect to estrogen levels, our data show sex-related
differences in levels of TLR2, FcγRI and FcγRIIIA in splenic and thioglycollate-elicited
macrophages, with male mice expressing higher levels compared to normal intact female mice.
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This finding is in contrast with results from other studies showing that TLR2 and CD16 surface
expression on PBMCs is significantly higher in women than in men, as is LPS-stimulated TNF-α
and IL-10 cytokine secretion (Ono, Tsujimoto et al. 2005). In the same study, the population of
monocytes bearing FcγRIIIA was significantly higher in females than in males, which may have
contributed to the observed differences in the levels of pro-inflammatory cytokine production.

FcγRIIIA expression on granulocytes appears to differ from the sex-related pattern seen on
moncyctes/macrophages. Indeed, gender seems to have no impact on FcγRIIIA expression on
granulocytes (Moxey-Mims, Frank et al. 1993). Yet, pregnancy has shown to be associated with
a lower intensity of granulocyte expression of FcγRIIIA (Naccasha, Gervasi et al. 2001).
Absence of FcγRIIIA has been reported in some patients with higher prevalence of autoimmune
diseases, although this absence was not associated with an increased risk of infection (de Haas,
Kleijer et al. 1995).

The overall functional state of monocytes is reflected in the expression of surface antigens such
as MHC class II, TLR and FcγR (Ono, Tsujimoto et al. 2005). FcγRIIIA-bearing monocytes
express higher levels of class II MHC molecules, adhesion molecules and chemokine receptors
and are able to more efficiently produce proinflammatory cytokines

as compared with

monocytes not expressing the receptor (Ziegler-Heitbrock, Fingerle et al. 1993). It has been
found that FcγRIIIA-bearing monocytes more strongly express TLR2 levels and TNF-α in
response to the TLR ligand lipopeptide (Iwahashi, Yamamura et al. 2004). This indicates that
TLR2 is relevant to FcγRIIIA-bearing monocyte activation. Moreover, these two receptors
appear to interact and regulate each other during inflammation. IL-12 is a pro-inflammatory
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cytokine secreted by macrophages in response to TLR2 stimulation and is MyD88-dependent. It
is important for both cell-mediated immune responses and to bias TH cells to a TH1 phenotype
(Trinchieri 1998; Underhill 2003). Down-regulation of IL-12 by macrophages is attributed to the
anti-inflammatory cytokines IL-4, IL-10 and TGF-β from T cells. Stimulation of macrophages
with bacterial products such as LPS (TLR2 agonist) induces high IL-12 production and low IL10 production (D'Andrea, Aste-Amezaga et al. 1993; Seki, Tsutsui et al. 2001). Co-ligation of
TLR2 and FcγRIII abrogates IL-12 production and increases IL-10 production (D'Andrea, Ma et
al. 1995; Gerber and Mosser 2001). FcγRIII ligation on macrophages thus seems to activate an
anti-inflammatory cell program that has a dampening effect on TLR-mediated pro-inflammatory
signals, possibly mediating inflammation.

Based on what we know of estrogen’s immunomodulatory role in the FRT, it is possible to
speculate that E2 plays a similar immunomodulatory role in helping to shape innate immunity
during systemic infection as well as to shape adaptive immune activation in response to
vaccination. Our results so far imply that ovariectomy consistently up-regulates TLR2, FcγRI
and FcγRIIIA gene expression, and that E2 treatment results in down-regulation of these genes in
macrophages. Furthermore, our data shows that the extent of modulation of gene expression in
response to CFP may be vaccine dose-dependent. The data obtained from this study will provide
some insight on how hormones, particularly estrogen, modulate macrophage gene expression
which may influence both the innate and adaptive immune response to M. tuberculosis. Studies
which address the interactions of the immune-endocrine systems in animal models are scarce.
These studies are important in order to gain a better understanding of the complex interactions
that determine the immune system’s response to stressors (e.g. bacterial aggression, vaccination,
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etc.) and how certain response may be modulated to either enhance or suppress a given response
for clinical purposes such as disease treatment or vaccine development.
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CHAPTER 6
Conclusions

There are many hormonal factors that collectively result in indirect modulation of the immune
response. These factors include those related to the production of estrogen, progesterone,
testosterone and their metabolites. Most of the research results currently available have implied
an immunosuppressive effect of estrogen. Pregnancy, a state of elevated estrogen and
progesterone, is associated with immunosuppression (Thong, Steele et al. 1973; Kovacs,
Messingham et al. 2002). However, it must be considered that in in vivo models, these results
may reflect a net effect of more complicated pathways. The influence of sex hormones on
immune responses has been studied by the administration or blockade of various hormones and
their metabolites. Results have uncovered important pro- and anti- inflammatory actions for sex
hormones. For example, estradiol is metabolized to several hydroxyestrogens (Mueck, Seeger et
al. 2002), and 4- and 16a-hydroxyestrogens are considered to be pro-inflammatory, while 2hydroxyestrogens are considered to be anti-inflammatory (Janele, Lang et al. 2006).
Progesterone is also considered to be anti-inflammatory under some circumstances, such as
during pregnancy, where along with estrogen, contributes to fetal tolerance. Within the context
of this complicated system, we have studied the effects of estrogen on the immune response
using an in vivo mouse model.

We have shown that estrogen acts indirectly and differentially on various components of the
immune system. Administration of proestrus levels of estrogen to ovariectomized mice results in
maximal vaccine-specific antibody responses in vivo, implying a net activating effect on B cell

117

function. A similar effect was seen in intact mice producing physiological levels of estrogen,
where their antibody responses were higher than those of ovariectomized mice, although this
may or may not be statistically significant, depending on the route of vaccine administration and
the type of vaccine formulation administered. Similar patterns of responses were seen when
examining the predominant T helper type response, where estrogen-replaced ovariectomized
mice produced maximal levels of vaccine-specific IgG1, indicating that estrogen imposes signals
that favor a predominant TH2 response, further confirming estrogen’s activating effect on B cell
function.

While specific antibody responses are important indicators of induction of immunity by
vaccination, there are several other cell types that are critically involved in the development of
this response. Macrophages lie at the crossroads of innate and adaptive immunity by virtue of
their many functions and signaling abilities. Thus, alterations in macrophage function can greatly
influence immune responses. We have shown that macrophage genes involved in innate and
adaptive immune function are differentially expressed depending on estrogen levels. Toll-like
receptor 2 (TLR2) is important in recognition and signaling in response to gram-positive and
gram-negative pathogen-derived molecules in the microenvironment as a fist line of defense. Our
results show that, in the absence of estrogen, macrophage TLR2 gene expression is greatly
enhanced, whereas in the presence of proestrus levels of estrogen, TLR2 gene expression is
greatly reduced. Furthermore, we found a strong sex-based correlation, where macrophages
isolated from male mice expressed significantly higher levels of TLR2.
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Another critical function of macrophages is to bind IgG molecules through surface receptors
known as FcγR. Upon binding, immune complex internalization results in signaling and antigen
presentation of antigenic epitopes to naïve T cells and therefore activation of the cellular immune
response. FcγR knockout mice display compromised cellular and humoral immune responses.
We have shown that in the absence of estrogen, there is an increase in FcγRI and FcγRIIIA gene
expression, whereas there is a reduction in expression of these genes in the presence of proestrus
estrogen levels. These genes are involved in signaling events that activate the immune system
and are therefore referred to as activating Fc receptors. Interestingly, we saw different patterns of
expression of FcγRIIB, which is involved in immune regulation by inhibiting overactivation of
the immune system, and is thus referred to as the inhibiting Fc receptor. We showed that
FcγRIIB gene expression is not influenced by estrogen. Similar to TLR2, we identified a strong
correlation between sex and FcγRI and FcγRIIIA gene expression where male mice expressed
higher levels compared to females. Consistent with the effects of estrogen, FcγRIIB gene
expression was not different with respect to sex.

It is important to note that FcγRIIB is the only FcγR expressed on B cells and therefore exerts
inbibitory signals when co-ligated with the BCR. FcγRIIB knockout mice display a phenotype
consistent with increased polyclonal Ig production and also spontaneously develop
autoantibodies in susceptible mouse strains. The finding that estrogen enhances B cell function
by increasing vaccine-specific antibody responses and promotes a strong TH2 response is
consistent with the modulation of FcγR gene expression in macrophages. Estrogen decreased
activating FcγR gene expression but did not interfere with FcγRIIB gene expression. Therefore,
estrogen may enhance the humoral immune response not only at the level of B cells, but also
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perhaps indirectly at the level of macrophages. Further studies should be carried out to assess the
effects of estrogen on surface expression of these receptors.

Public Health Implications
As we have discussed, estrogen regulates a plethora of biological activities. The implications of
this are important, particularly from a clinical standpoint. The ability to acutely change the
outcome of autoimmunity and/or improve responses to vaccination has eluded investigators for
over a century. Understanding the mechanisms that allow estrogen to accomplish rapid and
dramatic effects will allow the development of refined therapeutics that may or may not require
the broad-ranging effects of a sex steroid such as estrogen. This goal of this section is to discuss
some of the physiological factors that influence the hormonal balance in humans and animals
with an emphasis on the application of estrogen as an immunomodulator as well the need to
consider these factors within the context of immunological research.

Infectious diseases remain an important cause of morbidity and mortality in the elderly
population, who are more susceptible to severe infections and frequently respond poorly to
vaccination. This is partially a consequence of immunosenescence, or the functional
deterioration of the immune system with age (Grubeck-Loebenstein and Wick 2002). Some of
the effects of immunosenescence on immune function as it relates to vaccine responses have
been identified. These age-related alterations may partially result from hormonal changes in both
males and females.
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During menopause in females, ovarian function declines, resulting in serum estradiol levels
lower than in younger females (Chahal and Drake 2007). In males, there is a conversion of
dihydortestosterone to either testosterone or estradiol. The pathway resulting in testosterone
declines is potent in young males, but declines with age, whereas the pathway that results in
estradiol is maintained with age. Thus, males are not excluded from the potential age-related
changes of sex hormones, particularly estrogen.

A large percentage of post-menopausal females is under hormone replacement therapy (HRT) in
the United States. The importance of understanding the effects of estrogen and other
reproductive hormones on the body is exemplified in the results from the Women’s Health
Initiative (WHI) study. This study consisted of two parallel randomized, double-blind, placebo
controlled clinical trials of hormone therapy to determine whether conjugated equine estrogen
alone or in combination with progestin would reduce cardiovascular events in healthy postmenopausal women. The combined component of the WHI study was prematurely halted, as
women taking this treatment were determined to have increased risk of breast cancer as well as
heart disease and stroke (Rossouw, Anderson et al. 2002). The unopposed estrogen treatment
was continued to find that similar results were discovered in terms of heart disease and stroke,
but a striking decrease was seen with the incidence of breast cancer (Anderson, Limacher et al.
2004). Thus, there is a balance between the beneficial and harmful effects of estrogen on health.

Pregnancy is another reproductive phenomenon in which hormonal changes dictate immune
status for both the mother and fetus. The maintenance of pregnancy requires suppression of the
maternal immune system which would naturally recognize the developing fetus as a foreign
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allograft and mount a TH1 regulated cytotoxic immune response against it (Buyon 1998). During
pregnancy, many soluble factors are produced by the placenta which collectively skew maternal
immune regulation towards a protective TH2 phenotype. Therefore, based on the relative
contributions of sex hormones, vaccine responses during pregnancy may be greatly influenced.

The maternal immune status resulting from hormonal regulation also influences the developing
fetal immune system. Indeed, all newborns initially have an immunological milieu based on a
TH2 phenotype. Vaccination during the neonatal period must therefore overcome the dual
challenge of the inhibitory effect of maternally derived antibody and the natural TH2 regulatory
environment. Thus, it could be possible to redirect the neonatal immune response towards an
appropriate TH1 regulated reaction that confers protection. Understanding the contribution of
maternal and fetal hormones to immune status can aid in strategies to induce immune responses
with balanced TH1 and TH2 regulation in neonates (Morein, Blomqvist et al. 2007).

As mentioned previously, females are considerably more susceptible to developing autoimmune
diseases than males, and their symptoms are more severe than in males. Physiological changes in
estrogen contribute to this phenomenon. Animal models of autoimmune diseases have taught us
that low estrogen concentrations lead to exacerbation of symptoms in certain models (rheumatoid
arthritis and multiple sclerosis), while low estrogen ameliorates symptoms in other models
(systemic lupus erythematosus) (Da Silva 1999). Epidemiological evidence in humans confirms
this effect, where during pregnancy (high levels of estrogen), and post-partum and at menopause
(low levels of estrogen), onset and symptoms follow the same patterns. It is thought that
estrogen-dependent alteration of macrophage gene expression is one factor that contributes to
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autoimmune disease states, possibly through modulation of receptor gene expression and
function. These events are expected to have significant manifestations in immune responses in
these patients.

From our studies and others, there is currently a substantial amount of evidence implicating
estrogen as an immunomodulator, and based on such evidence, several applications should be
considered. The use of laboratory animals in immunological research is an invaluable tool for
human disease models. However, much of the studies that are conducted do not account for
possible gender and hormonal influences on the experimental immunological endpoints. Besides
just the direct effects of estrogen or sex hormones on immune parameters, it must also be
considered that conditions of stress may also influence immunity in humans and animal models
of research. As previously mentioned, the HPA axis, when activated, results in glucocorticoid
release. It is found that there is a gender dimorphism in the HPA axis itself, where females
produce higher levels of glucocorticoids in response to activation by immune aggression (Da
Silva 1999). Removal of testosterone in male mice results in higher production of
glucocorticoids, further confirming this effect. An imbalance in this pathway due to any number
of factors including that of sex hormones can have important consequences. On one hand,
excessive glucocorticoid production may lead to immunosuppression resulting in increased
infection or cancer. On the other hand, insufficient glucocorticoid production may lead to
increased vulnerability to autoimmune, inflammatory, or allergic disorders. Therefore, it is
important to consider environmental and stress factors that may strongly influence
immunological outcomes when conducting animal studies.
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One of the primary aims of vaccine research is to provide scientific evidence leading to
development of an agent that is capable of sufficiently stimulating the immune response in an
effort to protect against infectious disease. Therefore, in vaccine research it is imperative to
consider that the vaccine being tested may affect certain target populations and subpopulations
differently. To this end, biomedical research involving human subjects should be carried out in a
manner sufficient to elicit data from individuals from diverse groups and, in the case of clinical
trials, to examine differential effects on such groups. In March of 1994, NIH issued a policy on
the

inclusion

of

women

and

minorities

as

subjects

in

clinical

research

(http://grants.nih.gov/grants/guide/notice-files/not94-100.html). Given the hormonal fluctuations
in women and their resulting variations in immune status, it may be necessary to give increased
attention to the division of subpopulations of women, especially at the Phase III clinical trial
stage. Based on what we know of the effects of estrogen in particular, appropriate groups of
women subjects should be included based on hormonal status.

Hormonal effects on classical endocrine target organs such as the female reproductive tract,
mammary gland, ovary, and neuroendocrine system have been thoroughly studied, with
significant advancements in our understanding of estrogen actions and disease conditions.
Knowledge of the effects of estrogen in nonclassical endocrine organ systems, particularly the
immune system, arising from epidemiological and clinical data, is only now becoming available
based on the development and use of knock-out or transgenic animal models for the study of
both estrogen and ER activities. By expanding this field of research, it is reasonable to expect
that several important advancements will be made in the areas of vaccination against infectious
disease as well as treatment of immune disorders.
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